[
  {
    "Company": "Tenpoint Therapeutics",
    "Funding date": "2026-01-29",
    "Funding round": "B",
    "Funding amount": "$85M",
    "Investors": "Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio and Wille.",
    "Description": "With its eye drops for the age-related eye disease presbyopia just approved on Jan. 28, Tenpoint is now taking in $85 million to help launch the product, called Yuvezzi. The company plans to release the recently approved med in the second quarter of 2026.",
    "Therapeutic Area": "Ophthalmology (presbyopia, cataracts, geographic atrophy)",
    "Therapeutic Modality": "Small-molecule eye drops (topical combination)",
    "Lead Clinical Stage": "Clinical Phase 3 (approved; post-Phase 3)",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Breakthru Medicine",
    "Funding date": "2026-01-29",
    "Funding round": "A",
    "Funding amount": "$60M",
    "Investors": NaN,
    "Description": "Breakthru has emerged from stealth with $60 million, a molecular glue platform, and a pipeline of small molecules and antibody-drug conjugate payloads. The biotech was formed by Steve Potts, Ph.D.; Mark Mulvihill, Ph.D.; and Brian Barnett, M.D., in efforts to develop \"disruptive therapeutic modalities\" for cancer patients with high unmet need.",
    "Therapeutic Area": "Oncology (aggressive solid tumors; treatment-resistant cancers)",
    "Therapeutic Modality": "Small molecules (incl. molecular glues) and ADC payloads",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "TRexBio",
    "Funding date": "2026-01-27",
    "Funding round": NaN,
    "Funding amount": "$50M",
    "Investors": "Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors, Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly, Johnson & Johnson Innovation \u2013 JJDC, Pfizer Ventures, Polaris Partners and SV Health Investors.",
    "Description": "TRexBio has raised $50 million to support its Treg platform, which is designed to develop treatments for autoimmune and inflammatory diseases. These include TRB-061, a TNFR2 agonist currently being tested in a phase 1a/b trial for atopic dermatitis. The new cash will also go toward TRB-071 and TRB-081, which are both expected to launch in separate phase 1 trials in 2027.",
    "Therapeutic Area": "Immunology / Autoimmune & inflammatory diseases",
    "Therapeutic Modality": "Biologics (large-molecule Treg-targeted antibodies/agonists)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Likely",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Corxel Pharmaceuticals",
    "Funding date": "2026-01-22",
    "Funding round": "D",
    "Funding amount": "$287M",
    "Investors": "SR One, TCGX, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management, Invus, SilverArc Capital, RTW Investments, Hengdian Group Capital and others.",
    "Description": "Shanghai-headquartered Corxel Pharmaceuticals has raised $287 million to bankroll phase 2 studies of its oral GLP-1 receptor agonist.",
    "Therapeutic Area": "Cardiometabolic (obesity and type 2 diabetes)",
    "Therapeutic Modality": "Oral small-molecule GLP-1 receptor agonist",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes",
    "HQ City": "Shanghai",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Mendra",
    "Funding date": "2026-01-22",
    "Funding round": "A",
    "Funding amount": "$82M",
    "Investors": "OrbiMed, 8VC, 5AM Ventures, Lux Capital and Wing VC.",
    "Description": "A new AI biotech with a focus on rare disease is taking off in the Bay Area.",
    "Therapeutic Area": "Rare diseases (multi-indication portfolio)",
    "Therapeutic Modality": "Modality-agnostic rare-disease assets (small molecules and biologics)",
    "Lead Clinical Stage": "Not disclosed (likely clinical-stage and late-stage assets)",
    "Small molecule modality?": "Unclear",
    "HQ City": "Bay Area",
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Think Bioscience",
    "Funding date": "2026-01-21",
    "Funding round": "A",
    "Funding amount": "$55M",
    "Investors": "Regeneron Ventures, Innovation Endeavors, Janus Henderson Investors, T.A. Springer, CE-Ventures, MBX Capital, YK Bioventures, AV8 Ventures, CU Innovations and Buff Gold Ventures.",
    "Description": "The Colorado-based biotech will harness the cash to push forward its lead small molecule program for Noonan syndrome.",
    "Therapeutic Area": "Rare genetic disease (Noonan syndrome)",
    "Therapeutic Modality": "Small-molecule drugs discovered via synthetic biology",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": "The Colorado",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Exciva",
    "Funding date": "2026-01-20",
    "Funding round": "B",
    "Funding amount": "$59M",
    "Investors": "Gimv, EQT Life Sciences, Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi Ventures, Andera Partners and LBBW.",
    "Description": "The German biotech will use the funds to bankroll a phase 2 study of its lead neuropsychiatric candidate for treating agitation in patients with Alzheimer\u2019s disease. The therapy, called deraphan, is a combination of the cough suppressant dextromethorphan with a CYP2D6 inhibitor and a 5-HT2A/2C receptor inverse agonist.",
    "Therapeutic Area": "CNS / Neuropsychiatry (agitation associated with Alzheimer\u2019s disease)",
    "Therapeutic Modality": "Small-molecule combination therapy (dextromethorphan-based)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Likely",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Cytotheryx",
    "Funding date": "2026-01-16",
    "Funding round": "A",
    "Funding amount": "$60M",
    "Investors": "Ouroboros Family Founders Fund I, LP",
    "Description": "Cytotheryx, a preclinical cell therapy biotech, has circled up $60 million to advance its liver disease programs toward the clinic. The new cash infusion will also help the platform company grow its manufacturing infrastructure, according to the Minnesota business.",
    "Therapeutic Area": "Liver disease (acute liver failure, rare genetic & chronic liver diseases)",
    "Therapeutic Modality": "Cell therapy (hepatocyte-based) and bioartificial liver support",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Proxima",
    "Funding date": "2026-01-13",
    "Funding round": "Seed",
    "Funding amount": "$80M",
    "Investors": "DCVC, NVentures (NVIDIA\u2019s venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures and others.",
    "Description": "AI drug discovery outfit VantAI is rebranding to Proxima as it pockets $80 million to build a pipeline of \"proximity therapeutics,\" based on interactions between proteins.",
    "Therapeutic Area": "Multi-therapeutic area (platform for proximity therapeutics)",
    "Therapeutic Modality": "Small-molecule proximity therapeutics / molecular glues",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Vibrant Therapeutics",
    "Funding date": "2026-01-12",
    "Funding round": NaN,
    "Funding amount": "$61M",
    "Investors": "Pfizer Ventures, Apricot Capital, Bayland Capital, HSG, Northern Light Venture Capital and First Principle Venture",
    "Description": "China and U.S.-based Vibrant will use the cash to advance a pipeline led by VIB305, a masked T-cell engager prodrug designed to treat EGFR-expressing solid tumors.",
    "Therapeutic Area": "Oncology (EGFR-positive solid tumors)",
    "Therapeutic Modality": "Bispecific / masked T-cell engager (TCE) antibody prodrug",
    "Lead Clinical Stage": "Clinical Phase 1 (IND-cleared, first-in-human starting)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Kinaset Therapeutics",
    "Funding date": "2026-01-10",
    "Funding round": "B",
    "Funding amount": "$103M",
    "Investors": "RA Capital Management, Forge Life Science Partners, EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital, Atlas Venture, 5AM Ventures and Gimv.",
    "Description": "The respiratory disease-focused biotech will use the funds to finance a phase 2 dose-ranging study of frevecitinib, an inhaled dry powder pan-JAK inhibitor in development for patients with asthma.",
    "Therapeutic Area": "Respiratory (severe asthma)",
    "Therapeutic Modality": "Inhaled small\u2011molecule pan\u2011JAK inhibitor (dry powder)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Likely",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "AirNexis Therapeutics",
    "Funding date": "2026-01-09",
    "Funding round": "A",
    "Funding amount": "$200M",
    "Investors": "Frazier Life Sciences, OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital and Enavate Sciences, among others.",
    "Description": "AirNexis is taking flight with $200 million and a clinical-stage asset from Haisco Pharmaceutical Group that aims to treat lung disease. The PDE3/4 inhibitor is designed to expand the airways and reduce the release of inflammatory factors for patients with for chronic obstructive pulmonary disease.",
    "Therapeutic Area": "Respiratory (COPD)",
    "Therapeutic Modality": "Small\u2011molecule dual PDE3/4 inhibitor",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Likely",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Medipost",
    "Funding date": "2026-01-09",
    "Funding round": NaN,
    "Funding amount": "$140M",
    "Investors": "Skylake Equity Partners, Crescendo Equity Partners and a Korean growth equity fund.",
    "Description": "Stem cell therapy-focused Medipost's parent company, also called Medipost, has raised $140 million to launch a phase 3 trial for its investigational mesenchymal stem cell (MSC) therapy.",
    "Therapeutic Area": "Musculoskeletal / Orthopedic (knee osteoarthritis; cartilage defects)",
    "Therapeutic Modality": "Allogeneic mesenchymal stem cell therapy",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Parabilis Medicines",
    "Funding date": "2026-01-08",
    "Funding round": "F",
    "Funding amount": "$305M",
    "Investors": "RA Capital Management, Fidelity Management & Research Company, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, a life science-dedicated investment fund, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky Way Investments, GV, accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, General Catalyst, Invus, Farallon Capital Management, Foresite Capital, Rock Springs Capital, HBM Healthcare, Samsara BioCapital, Catalio Capital Management, Sixty Degree Capital, Alderline Group and others.",
    "Description": "The Massachusetts biotech, formerly known as FogPharma, will harness the new cash to advance FOG-001, recently renamed zolucatetide, toward a pivotal phase 3 trial in desmoid tumors.",
    "Therapeutic Area": "Oncology (desmoid tumors; advanced solid tumors)",
    "Therapeutic Modality": "Small\u2011molecule \u03b2\u2011catenin/TCF PPI inhibitor",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Alveus Therapeutics",
    "Funding date": "2026-01-08",
    "Funding round": "A",
    "Funding amount": "$160M",
    "Investors": "Andera Partners, New Rhein Healthcare Investors, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience Capital and others.",
    "Description": "Alveus has debuted with an impressive roster of executives ready to take the biotech\u2019s mission forward. Launched under the stewardship of former I-Mab CEO Raj Kannan, Alveus aims to advance an undisclosed number of obesity candidates.",
    "Therapeutic Area": "Metabolic / Obesity",
    "Therapeutic Modality": "Peptide hormone therapies (bifunctional GIPR antagonist / GLP\u20111R agonist; amylin\u2011based peptides)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Diagonal Therapeutics",
    "Funding date": "2026-01-08",
    "Funding round": "B",
    "Funding amount": "$125M",
    "Investors": "Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management L.P., Woodline Partners LP, Atlas Venture, BVF Partners, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, RV Invest, Velosity Capital, Biovision Ventures and Checkpoint Capital.",
    "Description": "Diagonal will use the raise to move its first-in-class rare disease drug DIAG723 into a first-in-human trial.",
    "Therapeutic Area": "Rare vascular diseases (HHT, PAH)",
    "Therapeutic Modality": "Clustering monoclonal antibodies",
    "Lead Clinical Stage": "Preclinical (FIH planned)",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "EpiBiologics",
    "Funding date": "2026-01-08",
    "Funding round": "B",
    "Funding amount": "$107M",
    "Investors": "Google Venture, Johnson & Johnson, Novartis Venture Fund, Aulis Capital, Avego BioScience Capital, Samsara BioCapital, Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital and Mission BioCapital.",
    "Description": "The San Francisco Bay Area-based biotech plans to use the cash is to take its lead bispecific antibody, dubbed EPI-326, into the clinic.",
    "Therapeutic Area": "Oncology (EGFR\u2011driven lung & head/neck cancer) / Immunology",
    "Therapeutic Modality": "Bispecific antibodies for extracellular protein degradation (EpiTACs)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": "The San Francisco Bay Area",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Beacon Therapeutics",
    "Funding date": "2026-01-08",
    "Funding round": "C",
    "Funding amount": "$75M",
    "Investors": "Life Sciences at Goldman Sachs Alternatives, the Retinal Degeneration Fund, the venture arm of Foundation Fighting Blindness, Syncona Limited, Forbion, Oxford Science Enterprises and Advent Life Sciences.",
    "Description": "As the biotech awaits phase 3 data in X-linked retinitis pigmentosa for its lead candidate laru-zova, Beacon is bringing in more than $75 million to get the gene therapy across the finish line.",
    "Therapeutic Area": "Ophthalmology (X\u2011linked retinitis pigmentosa)",
    "Therapeutic Modality": "AAV gene therapy",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Soley Therapeutics",
    "Funding date": "2026-01-07",
    "Funding round": "C",
    "Funding amount": "$200M",
    "Investors": "Surveyor Capital, HRTG Partners, RWN Management, Doug Leone Family Fund, Breyer Capital and GordonMD Global Investments",
    "Description": "The South San Francisco-based company\u2019s pipeline uses a cell stress sensing platform that harnesses artificial intelligence and \u201ccomputer vision\u201d to analyze thousands of responses in human cells.",
    "Therapeutic Area": "Oncology (lead AML program); neurodegenerative & metabolic",
    "Therapeutic Modality": "Small\u2011molecule stress\u2011modulating drugs (cell\u2011stress sensing platform)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": "The South San Francisco",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Rakuten Medical",
    "Funding date": "2026-01-07",
    "Funding round": "F",
    "Funding amount": "$100M",
    "Investors": "TaiAx Life Science Fund, Daiwa Securities, Mitsui Sumitomo Insurance, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten Group and Rakuten Medical CEO Mickey Mikitani",
    "Description": "San Diego-based Rakuten Medical is focused on a global phase 3 trial evaluating ASP-1929 in combination with Merck & Co.\u2019s Keytruda as a first-line treatment.",
    "Therapeutic Area": "Oncology (recurrent head & neck squamous cell carcinoma)",
    "Therapeutic Modality": "Antibody\u2013dye conjugate photoimmunotherapy",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "Unclear",
    "HQ City": "San Diego",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Corsera Health",
    "Funding date": "2026-01-07",
    "Funding round": "A",
    "Funding amount": "$80M",
    "Investors": "Forbion, Population Health Partners and others.",
    "Description": "RNAi outfit Corsera will use the raise to support its first clinical trial, a phase 1 study of PCSK9-targeting siRNA COR-1004 that just began dosing patients.",
    "Therapeutic Area": "Cardiovascular (LDL-C reduction and blood pressure control)",
    "Therapeutic Modality": "RNA therapy (subcutaneously administered siRNA / RNAi medicine)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Poplar Therapeutics",
    "Funding date": "2026-01-07",
    "Funding round": "A",
    "Funding amount": "$50M",
    "Investors": "SR One, Vida Ventures and Platanus",
    "Description": "The immunology company, previously known as Phylaxis Bioscience, will use the series A funds to advance its pipeline of anti-IgE therapies for food allergy and other atopic conditions.",
    "Therapeutic Area": "Immunology / Allergy (food allergy, asthma, atopic dermatitis)",
    "Therapeutic Modality": "Biologics (next-generation anti-IgE monoclonal antibody)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Syneron Bio",
    "Funding date": "2025-12-18",
    "Funding round": "A & A extension",
    "Funding amount": "$100M",
    "Investors": "AstraZeneca; AZ-CICC Healthcare Investment Fund; Pfizer Biotech Development Investment Fund; GL Ventures; 5Y Capital; Sinovation Capital; Lenovo Capital; Gree Capital; KHK fund",
    "Description": "Macrocyclic peptide drug discovery platform Synova; funds to bolster platform and advance multiple programs toward clinic.",
    "Therapeutic Area": "Oncology and chronic diseases (incl. rare, autoimmune, metabolic)",
    "Therapeutic Modality": "Macrocyclic peptide therapeutics (Synova platform)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Syremis Therapeutics",
    "Funding date": "2025-12-18",
    "Funding round": "A",
    "Funding amount": "$165M",
    "Investors": "Dexcel Pharma; Third Rock Ventures; Bain Capital Life Sciences; GV (Google Ventures); QVT; Pictet",
    "Description": "Launched to develop treatments for schizophrenia/psychotic disorders; lead program ST-905 dual M1/M4 muscarinic agonist in Phase 1.",
    "Therapeutic Area": "CNS / Neuropsychiatry (schizophrenia and other neuropsychiatric disorders)",
    "Therapeutic Modality": "Small-molecule dual M1/M4 muscarinic agonist",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes (muscarinic agonist; likely small molecule)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Addition Therapeutics",
    "Funding date": "2025-12-17",
    "Funding round": "N/A (launch financing)",
    "Funding amount": "$100M",
    "Investors": "SR One; Pivotal Life Sciences; Abingworth; Osage University Partners; Gates Foundation; BEVC",
    "Description": "Launch financing for PRINT platform (Precise RNA Mediated Insertion of Transgenes) to enable one-time genetic medicines; initial targets not detailed; Gates grant for HIV work.",
    "Therapeutic Area": "Chronic and rare diseases (multi-indication genetic medicine)",
    "Therapeutic Modality": "All-RNA, non-viral LNP gene insertion platform (PRINT genetic medicine)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (genetic medicine)",
    "HQ City": "South San Francisco",
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Aeovian Pharmaceuticals",
    "Funding date": "2025-12-16",
    "Funding round": "B",
    "Funding amount": "$55M",
    "Investors": "Luma Group; CTI Life Sciences Fund; Foresite Capital; SymBiosis; TSC Alliance Endowment Fund; Wilson Sonsini; Apollo Health Ventures; Hevolution; Sofinnova Investments; venBio",
    "Description": "Funds to complete Phase 2 study of AV078 in tuberous sclerosis complex-related refractory epilepsy.",
    "Therapeutic Area": "CNS / Rare epilepsy (TSC-related refractory epilepsy)",
    "Therapeutic Modality": "Small-molecule CNS-penetrant selective mTORC1 inhibitor",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Ambros Therapeutics",
    "Funding date": "2025-12-16",
    "Funding round": "A",
    "Funding amount": "$125M",
    "Investors": "RA Capital; Enavate Sciences; Abiogen Pharma; Janus Henderson; Arkin Bio; Balyasny; Transhuman Capital; Adage; other life sciences investors",
    "Description": "Funds Phase 3 program for neridronate in complex regional pain syndrome type 1 (already approved in Italy; targeting future FDA path).",
    "Therapeutic Area": "Pain (Complex Regional Pain Syndrome type 1 / CRPS-1)",
    "Therapeutic Modality": "Small-molecule bisphosphonate (neridronate)",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "No (neridronate is a small molecule? actually bisphosphonate)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Chai Discovery",
    "Funding date": "2025-12-15",
    "Funding round": "B",
    "Funding amount": "$130M",
    "Investors": "Oak HC/FT; General Catalyst; Thrive Capital; OpenAI; Dimension; Menlo Ventures; Lachy Groom; Yosemite; Neo; SV Angel; Emerson Collective; Glade Brook",
    "Description": "AI drug design company building computer-aided design suite for therapeutics; previously launched Chai 2 antibody design model; Mikael Dolsten joined board.",
    "Therapeutic Area": "Platform (biologics; antibody and protein binder discovery)",
    "Therapeutic Modality": "AI / computational antibody & protein design (no lead therapeutic yet)",
    "Lead Clinical Stage": "Preclinical (discovery-stage platform)",
    "Small molecule modality?": "Unclear (platform)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Prolynx",
    "Funding date": "2025-12-11",
    "Funding round": "A",
    "Funding amount": "$70M",
    "Investors": "5AM Ventures; OrbiMed; Monograph Capital",
    "Description": "Developing long-acting treatments for obesity and other metabolic diseases with once-monthly/quarterly dosing; moving portfolio toward IND-enabling and PoC.",
    "Therapeutic Area": "Metabolic / Obesity and weight management",
    "Therapeutic Modality": "Long-acting peptide therapies for obesity (GLP-1, amylin etc.)",
    "Lead Clinical Stage": "Preclinical / early clinical (long-acting obesity candidates)",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "D3 Bio",
    "Funding date": "2025-12-10",
    "Funding round": "B",
    "Funding amount": "$108M",
    "Investors": "IDG Capital; SongQing Capital; WuXi AppTec Corporate Venture Fund; Temasek; HSG; MPCi; Medicxi",
    "Description": "Funding to advance KRAS inhibitor elisrasib (KRAS G12C) into Phase 3; planned mono/combination studies in NSCLC and mCRC.",
    "Therapeutic Area": "Oncology (KRAS G12C-mutant cancers incl. NSCLC, CRC)",
    "Therapeutic Modality": "Small-molecule KRAS G12C inhibitor (elisrasib / D3S-001)",
    "Lead Clinical Stage": "Clinical Phase 3 (global pivotal program planned)",
    "Small molecule modality?": "Yes (KRAS inhibitor)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "China"
  },
  {
    "Company": "SanegeneBio",
    "Funding date": "2025-12-08",
    "Funding round": "B",
    "Funding amount": "$110M",
    "Investors": "Unnamed industrial investor; unnamed sovereign wealth fund; Sino Biopharm; Legend Capital; Vivo; Invus; SymBiosis; Guofa; TruMed; Lake Bleu; Qiming; K2; TF Capital; Oriza; Northern Light; others",
    "Description": "RNAi-focused; funds to push clinical candidates toward registrational studies; multiple liver and extrahepatic programs; three Phase 2 liver assets most advanced.",
    "Therapeutic Area": "Metabolic / Liver and cardiometabolic diseases (plus autoimmune)",
    "Therapeutic Modality": "RNA therapy (siRNA / RNAi-based therapeutics)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No (RNAi)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "OTR Therapeutics",
    "Funding date": "2025-12-04",
    "Funding round": "A",
    "Funding amount": "$100M",
    "Investors": "Pfizer Ventures; True Light Capital; Sirona Capital",
    "Description": "China-based; funds (raised earlier, announced in Dec) to expand Shanghai Zhangjiang hub capability.",
    "Therapeutic Area": "Multi-therapeutic area (early-stage innovations incl. neurology and chronic diseases)",
    "Therapeutic Modality": "Modality-agnostic (in-licensed early-stage small molecules and biologics)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": "Shanghai",
    "HQ State/Region": NaN,
    "HQ Country": "China"
  },
  {
    "Company": "SciNeuro Pharmaceuticals",
    "Funding date": "2025-12-04",
    "Funding round": NaN,
    "Funding amount": "$53M",
    "Investors": "LAV; ARCH Venture Partners; plus new and existing investors",
    "Description": "Neurodegenerative disease pipeline targeting Lp-PLA2, beta amyloid and LRRK2 pathways; also received Michael J. Fox Foundation grant for Parkinson's work.",
    "Therapeutic Area": "CNS / Neurodegenerative diseases",
    "Therapeutic Modality": "Small-molecule therapeutics targeting Lp-PLA2, beta-amyloid, LRRK2 and other CNS pathways",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Triana Biomedicines",
    "Funding date": "2025-12-03",
    "Funding round": "B",
    "Funding amount": "$120M",
    "Investors": "RA Capital; Atlas; Lightspeed; Pfizer Ventures; Surveyor Capital",
    "Description": "Funds to take ALK-targeted molecular glue degrader TRI-611 into clinic; advancing pipeline of genomically-defined molecular glue degraders.",
    "Therapeutic Area": "Oncology (ALK+ non-small cell lung cancer and other genomically defined tumors)",
    "Therapeutic Modality": "Small-molecule molecular glue degrader (ALK-targeted)",
    "Lead Clinical Stage": "Preclinical (FIH planned)",
    "Small molecule modality?": "Yes (molecular glue degrader)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Protego Biopharma",
    "Funding date": "2025-12-01",
    "Funding round": "B",
    "Funding amount": "$130M",
    "Investors": "Novartis Venture Fund; Forbion; Omega; Droia; YK Bioventures; Digitalis; Vida; MPM BioImpact; Lightspeed; Scripps Research",
    "Description": "Advancing AL amyloidosis candidate PROT-001 toward pivotal trials; aiming for first disease-modifying therapy for AL amyloidosis.",
    "Therapeutic Area": "Rare disease / Cardiac amyloidosis (AL amyloidosis)",
    "Therapeutic Modality": "Small-molecule protein stabilizer (light-chain folding corrector)",
    "Lead Clinical Stage": "Clinical Phase 3 (pivotal trial planned)",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Aspen Neuroscience",
    "Funding date": "2025-11-20",
    "Funding round": "C",
    "Funding amount": "$115M",
    "Investors": "OrbiMed; ARCH; Frazier; Revelation; Medical Excellence; S32; Axon; LYFE; LifeForce; Gilead Kite; Balyasny; Cormorant; Prebys; others",
    "Description": "Funding to support Phase 1/2 study of ANPD001 (patient skin cells -> neurons transplanted for Parkinson's) and prepare for Phase 3.",
    "Therapeutic Area": "CNS / Parkinson\u2019s disease",
    "Therapeutic Modality": "Autologous iPSC-derived neuron replacement cell therapy",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No (cell therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Solve Therapeutics",
    "Funding date": "2025-11-17",
    "Funding round": NaN,
    "Funding amount": "$120M",
    "Investors": "Yosemite; Abingworth; Ally Bridge; B Capital; Balyasny; Merck & Co.; SymBiosis; Alexandria; AyurMaya; DC Global; General Atlantic; Citadel Surveyor",
    "Description": "Round to support two clinical ADCs and expansion of CloakLink linker platform for ADC stability / payload properties; total capital $321M.",
    "Therapeutic Area": "Oncology (solid tumors)",
    "Therapeutic Modality": "Antibody-drug conjugates (ADCs) using CloakLink linker platform",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No (ADCs)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Artios Pharma",
    "Funding date": "2025-11-17",
    "Funding round": "D",
    "Funding amount": "$115M",
    "Investors": "SV Health Investors; RA Capital; Janus Henderson; unnamed existing investors",
    "Description": "Funds DDR-targeting oncology pipeline; expand clinical program for lead alnodesertib; enroll more patients in pancreatic and colorectal cancer.",
    "Therapeutic Area": "Oncology (DDR-deficient cancers incl. ATM-negative colorectal and pancreatic)",
    "Therapeutic Modality": "Small-molecule DNA damage response inhibitors (ATR inhibitor alnodesertib)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes (alnodesertib is a small-molecule DDR inhibitor)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "UK"
  },
  {
    "Company": "Gate Bioscience",
    "Funding date": "2025-11-13",
    "Funding round": "B",
    "Funding amount": "$65M",
    "Investors": "Forbion; Eli Lilly; Versant; a16z Bio + Health; GV; ARCH",
    "Description": "Small-molecule specialist; funds for IND-enabling and Phase 1 studies of lead programs; aims to block targets from crossing cell membranes.",
    "Therapeutic Area": "Multi-therapeutic area (inflammatory, neurodegenerative and oncology indications)",
    "Therapeutic Modality": "Small-molecule protein elimination (Molecular Gates targeting extracellular proteins)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Braveheart Bio",
    "Funding date": "2025-11-05",
    "Funding round": "A",
    "Funding amount": "$185M",
    "Investors": "a16z Bio + Health; Forbion; OrbiMed; Enavate Sciences; Frazier",
    "Description": "Heart disease drug developer; entered HCM space via deal for selective myosin inhibitor from Jiangsu Hengrui; competing with Camzyos / aficamten.",
    "Therapeutic Area": "Cardiovascular (hypertrophic cardiomyopathy / HCM)",
    "Therapeutic Modality": "Small-molecule selective cardiac myosin inhibitor",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "Yes (myosin inhibitor)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Azalea Therapeutics",
    "Funding date": "2025-11-04",
    "Funding round": "Combined seed & A",
    "Funding amount": "$82M",
    "Investors": "Third Rock; RA Capital; Yosemite; Sozo; unnamed individuals",
    "Description": "Genome editing company using dual-vector approach for permanent editing; pushing in vivo CAR-T for B-cell malignancies into clinic in 12\u201318 months.",
    "Therapeutic Area": "Oncology (B\u2011cell malignancies, multiple myeloma; future autoimmune)",
    "Therapeutic Modality": "In vivo CAR\u2011T and other in vivo cell therapies via dual\u2011vector genome editing",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (gene/cell therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Neok Bio",
    "Funding date": "2025-11-03",
    "Funding round": "A",
    "Funding amount": "$75M",
    "Investors": "ABL Bio",
    "Description": "Exited stealth to take two bispecific ADCs from ABL Bio into clinic; plans to file early next year; U.S. studies mid-2026.",
    "Therapeutic Area": "Oncology (solid tumors)",
    "Therapeutic Modality": "Bispecific antibody\u2011drug conjugates (ADCs)",
    "Lead Clinical Stage": "Preclinical (FIH planned)",
    "Small molecule modality?": "No (ADCs)",
    "HQ City": NaN,
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "AAVantgarde Bio",
    "Funding date": "2025-11-03",
    "Funding round": "B",
    "Funding amount": "$141M",
    "Investors": "Schroders Capital; Atlas; Forbion; Amgen Ventures; Athos; CDP Venture Capital; Columbia IMC; Neva SGR; Sixty Degree; XGen; Willett; Longwood; Sofinnova",
    "Description": "Italian gene therapy company; funds to advance AAVB-039 (Stargardt) and AAVB-081 (Usher Type 1B retinitis pigmentosa) in Phase 1/2.",
    "Therapeutic Area": "Ophthalmology / Inherited retinal diseases (Stargardt disease; Usher syndrome type 1B retinitis pigmentosa)",
    "Therapeutic Modality": "Dual\u2011vector AAV gene therapy",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No (gene therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Italy"
  },
  {
    "Company": "Hemab Therapeutics",
    "Funding date": "2025-10-27",
    "Funding round": "C",
    "Funding amount": "$157M",
    "Investors": "Sofinnova Partners; Avoro; RA Capital; Novo Holdings; Access Biotechnology; Deep Track; HealthCap; Invus; Avoro Ventures; Maj Invest Equity; Rock Springs; unnamed global asset manager",
    "Description": "Rare bleeding disorders; funds to advance sutacimig for Glanzmann thrombasthenia.",
    "Therapeutic Area": "Hematology / Rare bleeding disorders (Glanzmann thrombasthenia, von Willebrand disease, factor VII deficiency)",
    "Therapeutic Modality": "Monoclonal antibody prophylactic therapy (sutacimig)",
    "Lead Clinical Stage": "Clinical Phase 2 (pivotal Phase 3 planned)",
    "Small molecule modality?": "No (midstage biologic)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Electra Therapeutics",
    "Funding date": "2025-10-22",
    "Funding round": "C",
    "Funding amount": "$183M",
    "Investors": "Nextech; EQT Life Sciences; Sanofi; HBM Healthcare; Mubadala; OrbiMed; Redmile; New Leaf; Westlake BioPartners; Cormorant; Blue Owl; RA Capital",
    "Description": "Funds pivotal Phase 2/3 for ELA026, monoclonal antibody targeting signal regulatory proteins to deplete pathological immune cells.",
    "Therapeutic Area": "Immunology / Severe inflammatory & immune disorders (e.g., secondary HLH)",
    "Therapeutic Modality": "Monoclonal antibody targeting SIRP to deplete pathological myeloid cells and T lymphocytes",
    "Lead Clinical Stage": "Clinical Phase 2 (pivotal program in sHLH)",
    "Small molecule modality?": "No (mAb)",
    "HQ City": "South San Francisco",
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Elevara Medicines",
    "Funding date": "2025-10-21",
    "Funding round": "A",
    "Funding amount": "$70M",
    "Investors": "Forbion; Sofinnova Partners; Weatherden; Monograph Capital",
    "Description": "UK biotech; Phase 2-ready oral CDK4/6 inhibitor (licensed from Teijin) for rheumatoid arthritis; launching Phase 2 by end of year.",
    "Therapeutic Area": "Immunology / Rheumatology (rheumatoid arthritis)",
    "Therapeutic Modality": "Oral small\u2011molecule CDK4/6 inhibitor",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes (oral CDK4/6 inhibitor)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "UK"
  },
  {
    "Company": "Adcytherix",
    "Funding date": "2025-10-16",
    "Funding round": "A",
    "Funding amount": "$122M",
    "Investors": "Bpifrance; Kurma; Andera; Angelini; Citadel Surveyor; aMoon; existing investors",
    "Description": "French ADC company; funds to push lead ADCX-020 into clinical trials and expand ADC pipeline; filing in US/UK/Canada/Europe.",
    "Therapeutic Area": "Oncology (solid tumors with high unmet need)",
    "Therapeutic Modality": "Antibody\u2011drug conjugates (ADCs; lead candidate ADCX\u2011020)",
    "Lead Clinical Stage": "Clinical Phase 1 (FIH starting)",
    "Small molecule modality?": "No (ADCs)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "France"
  },
  {
    "Company": "Peptilogics",
    "Funding date": "2025-10-16",
    "Funding round": "B2",
    "Funding amount": "$78M",
    "Investors": "Presight Capital; Thiel Bio; Founders Fund; AMR Action Fund; Narya Capital; Beyond Ventures",
    "Description": "Pittsburgh-based; funds Phase 2/3 trial of lead asset zaloganan in prosthetic joint infections; total financing $120M.",
    "Therapeutic Area": "Infectious disease / Orthopedic infections (prosthetic joint infection)",
    "Therapeutic Modality": "Engineered antimicrobial peptide therapeutic (zaloganan / PLG0206)",
    "Lead Clinical Stage": "Clinical Phase 2/3 (pivotal trial)",
    "Small molecule modality?": "Unclear",
    "HQ City": "Pittsburgh",
    "HQ State/Region": "PA",
    "HQ Country": "USA"
  },
  {
    "Company": "Tubulis",
    "Funding date": "2025-10-15",
    "Funding round": "C",
    "Funding amount": "$361M",
    "Investors": "Venrock; Wellington; Ascenta; Nextech; EQT; Frazier; Andera; Deep Track; Bayern Kapital; Fund+; HTGF; OCCIDENT; Seventure",
    "Description": "German ADC developer; funds to expand clinical development of lead ADC TUB-040 (NaPi2b) in ovarian and NSCLC.",
    "Therapeutic Area": "Oncology (platinum\u2011resistant ovarian cancer; adenocarcinoma NSCLC)",
    "Therapeutic Modality": "Antibody\u2011drug conjugate (NaPi2b\u2011targeting exatecan ADC, TUB\u2011040)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No (ADCs)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Germany"
  },
  {
    "Company": "Renasant Bio",
    "Funding date": "2025-07-10",
    "Funding round": "Seed",
    "Funding amount": "$54.5M",
    "Investors": "5AM Ventures; Atlas Venture; OrbiMed; Qiming Ventures",
    "Description": "California-based; oral small-molecule corrector/potentiator programs for genetic kidney failure; incubated by 4:59 Initiative.",
    "Therapeutic Area": "Renal / Genetic kidney disease (ADPKD)",
    "Therapeutic Modality": "Oral small\u2011molecule corrector and potentiator therapies",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Nuclidium",
    "Funding date": "2025-07-10",
    "Funding round": "B",
    "Funding amount": "$99M",
    "Investors": "Kurma Growth Opportunities; Angelini; Wellington Partners; Neva SGR; DeepTech & Climate Fonds; Bayern Kapital; Eurazeo; Vives; NRW.BANK; HighLight; other existing investors",
    "Description": "Swiss and German radiopharma company; copper-based radiotheranostics diagnostics/therapeutics; early clinical data in prostate cancer imaging agent copper-61.",
    "Therapeutic Area": "Oncology / Radiopharmaceuticals (prostate cancer imaging)",
    "Therapeutic Modality": "Radiopharmaceutical (copper\u2011based radiotheranostics)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No (radiopharma)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Switzerland/Germany"
  },
  {
    "Company": "Actithera",
    "Funding date": "2025-07-09",
    "Funding round": "A",
    "Funding amount": "$75.5M",
    "Investors": "M Ventures; Hadean; Sofinnova Partners; 4BIO; Bioqube; Innovestor; Investinor; Surveyor; Arkin Bio Ventures II",
    "Description": "Norway and Cambridge, MA-based radioconjugates targeting fibroblast activation protein for oncology; aiming for longer retention in tumors.",
    "Therapeutic Area": "Oncology (fibroblast activation protein\u2013positive tumors)",
    "Therapeutic Modality": "Radioconjugate therapy",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (radioconjugates)",
    "HQ City": "Cambridge",
    "HQ State/Region": "MA",
    "HQ Country": "USA/Norway"
  },
  {
    "Company": "Actio Biosciences",
    "Funding date": "2025-06-18",
    "Funding round": "B",
    "Funding amount": "$66M",
    "Investors": "Regeneron Ventures; Deerfield; Canaan; Droia; Euclidean Capital",
    "Description": "San Diego-based; advancing TRPV4 inhibitor and KCNT1 inhibitor programs.",
    "Therapeutic Area": "Oncology / Genetic diseases (TRPV4, KCNT1)",
    "Therapeutic Modality": "Small\u2011molecule inhibitors",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes (inhibitors)",
    "HQ City": "San Diego",
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Draig Therapeutics",
    "Funding date": "2025-06-18",
    "Funding round": "A",
    "Funding amount": "$140M",
    "Investors": "Access Biotechnology; Canaan; SR One; Sanofi Ventures; Schroders; SV Health; ICG",
    "Description": "Welsh biotech; funds Phase 2 trials of depression candidate DT-101 (AMPA receptor modulator).",
    "Therapeutic Area": "CNS (depression)",
    "Therapeutic Modality": "Small\u2011molecule AMPA receptor modulator",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear (likely small molecule)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "UK (Wales)"
  },
  {
    "Company": "SpliceBio",
    "Funding date": "2025-06-11",
    "Funding round": "B",
    "Funding amount": "$135M",
    "Investors": "EQT Life Sciences; Sanofi Ventures; Roche Venture Fund; NEA; UCB Ventures; Ysios; Gilde; Novartis Venture Fund; Asabys",
    "Description": "Spain-based; advancing AAV gene therapy for Stargardt disease (Phase 1/2) and other AAV programs.",
    "Therapeutic Area": "Ophthalmology / Inherited retinal diseases (Stargardt)",
    "Therapeutic Modality": "AAV gene therapy",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No (gene therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Spain"
  },
  {
    "Company": "Antares Therapeutics",
    "Funding date": "2025-06-10",
    "Funding round": "A",
    "Funding amount": "$177M",
    "Investors": "Omega; Atlas; Lightspeed; BVF; Cormorant; Vinyanshu; Abingworth; Invus; Tenmile; Vida; Willett Advisors",
    "Description": "Scorpion spinout to advance 3 preclinical precision medicine candidates; includes programs from AstraZeneca transcription factor deal.",
    "Therapeutic Area": "Oncology / Precision medicine",
    "Therapeutic Modality": "Small\u2011molecule targeted therapies",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Mosanna Therapeutics",
    "Funding date": "2025-06-09",
    "Funding round": "A",
    "Funding amount": "$80M",
    "Investors": "Pivotal bioVenture; EQT; Forbion; Broadview; Norwest; Forty51; Supermoon; High-Tech Gr\u00fcnderfonds",
    "Description": "Obstructive sleep apnea; nighttime nasal spray MOS118 through Phase 2; expand pipeline.",
    "Therapeutic Area": "Respiratory / Sleep disorders (obstructive sleep apnea)",
    "Therapeutic Modality": "Small\u2011molecule nasal spray (MOS118)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Allay Therapeutics",
    "Funding date": "2025-06-05",
    "Funding round": "D",
    "Funding amount": "$57.5M",
    "Investors": "Lightstone; ClavystBio; NEA; Arboretum; Vertex Growth; Vertex Ventures Healthcare; Brandon; IPD; EDBI; SGInnovate; HSBC Innovation Banking",
    "Description": "Phase 2b for analgesic ATX101 in post-surgical knee pain; exploring other indications; Phase 3 planned next year.",
    "Therapeutic Area": "Pain (post\u2011surgical knee pain)",
    "Therapeutic Modality": "Small\u2011molecule analgesic (ATX101)",
    "Lead Clinical Stage": "Clinical Phase 2b",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "SpyGlass Pharma",
    "Funding date": "2025-06-02",
    "Funding round": "D",
    "Funding amount": "$75M",
    "Investors": "Sands Capital; NEA; RA Capital; Vensana; Samsara; Vertex Ventures HC",
    "Description": "Funds two Phase 3 trials of glaucoma asset bimatoprost; earlier-stage AMD, cataracts, uveitis assets.",
    "Therapeutic Area": "Ophthalmology (glaucoma; AMD; cataracts; uveitis)",
    "Therapeutic Modality": "Small\u2011molecule ocular therapies (incl. bimatoprost implant)",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "Yes (bimatoprost)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Vima Therapeutics",
    "Funding date": "2025-05-29",
    "Funding round": "A",
    "Funding amount": "$60M",
    "Investors": "Atlas Venture; Access Industries; Canaan",
    "Description": "Launch; pipeline led by VIM0423 (preclinical oral therapy) already in Phase 1 for dystonia; preparing Phase 2.",
    "Therapeutic Area": "Neurology / Movement disorders (dystonia)",
    "Therapeutic Modality": "Oral small\u2011molecule therapy",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes (oral)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "AusperBio",
    "Funding date": "2025-05-28",
    "Funding round": "B+",
    "Funding amount": "$50M",
    "Investors": "Qiming; CDH; Genesis Capital; YuanBio; HanKang; Sherpa Capital",
    "Description": "Added financing to support AHB-137 unconjugated antisense oligo for chronic hepatitis B; scale manufacturing partnerships; pipeline growth.",
    "Therapeutic Area": "Infectious disease / Liver (chronic hepatitis B)",
    "Therapeutic Modality": "Antisense oligonucleotide (ASO) therapy",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "No (ASO)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Grin Therapeutics",
    "Funding date": "2025-05-27",
    "Funding round": "D",
    "Funding amount": "$140M",
    "Investors": "Angelini Pharma; Blackstone Life Sciences",
    "Description": "Financing plus $50M upfront from Angelini for rights to epilepsy drug radiprodil outside North America.",
    "Therapeutic Area": "Neurology / Genetic neurodevelopmental disorders (GRIN\u2011NDD)",
    "Therapeutic Modality": "Small\u2011molecule NMDA\u2011NR2B modulator (radiprodil)",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "Yes (radiprodil is small molecule)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Syndeio Biosciences",
    "Funding date": "2025-05-27",
    "Funding round": NaN,
    "Funding amount": "$90M",
    "Investors": "Catalio; Innoviva; Tenmile; Luson; Palo Santo; AbbVie and Eli Lilly as strategic shareholders",
    "Description": "Debuting to create precision neurotherapeutics to repair synaptic function; lead candidate zelquistinel in Phase 2 for MDD; expected Alzheimer's study.",
    "Therapeutic Area": "CNS / Psychiatry (major depressive disorder; Alzheimer\u2019s biomarker program)",
    "Therapeutic Modality": "Small\u2011molecule synapse\u2011targeting neurotherapeutic (zelquistinel)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes (zelquistinel is small molecule)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Juvenescence",
    "Funding date": "2025-05-21",
    "Funding round": "B-1",
    "Funding amount": "$76M",
    "Investors": "M42 (Abu Dhabi) with follow-on from existing investors",
    "Description": "UK-based anti-aging; advancing portfolio; has PAI-1 inhibitor in clinic for fibrosis.",
    "Therapeutic Area": "Fibrosis / Aging\u2011related diseases",
    "Therapeutic Modality": "Oral small\u2011molecule PAI\u20111 inhibitor",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes (PAI-1 inhibitor likely small molecule)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "UK"
  },
  {
    "Company": "ReproNovo",
    "Funding date": "2025-05-21",
    "Funding round": "A",
    "Funding amount": "$65M",
    "Investors": "Jeito Capital; AXA IM Alts; M Ventures; Ysios; ALSA Ventures",
    "Description": "Switzerland-based reproductive health; Phase 2 trials for leflutrozole (aromatase inhibitor) in male infertility and nolasiban (oxytocin receptor antagonist) for embryo implantation.",
    "Therapeutic Area": "Reproductive health (male infertility due to low testosterone)",
    "Therapeutic Modality": "Oral small\u2011molecule aromatase inhibitor (leflutrozole / RPN\u2011001)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Switzerland"
  },
  {
    "Company": "CellCentric",
    "Funding date": "2025-05-19",
    "Funding round": "C",
    "Funding amount": "$120M",
    "Investors": "RA Capital; Forbion; Avego; American Cancer Society VC arm",
    "Description": "Pfizer-backed British biotech; funds Phase 2/3 in multiple myeloma for oral p300/CBP inhibitor; preparing Phase 3 and potential accelerated approval filing.",
    "Therapeutic Area": "Oncology (multiple myeloma)",
    "Therapeutic Modality": "Oral small\u2011molecule p300/CBP inhibitor (inobrodib)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes (oral inhibitor)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "UK"
  },
  {
    "Company": "Azafaros",
    "Funding date": "2025-05-13",
    "Funding round": "B",
    "Funding amount": "$147M",
    "Investors": "Jeito; Forbion Growth; Seroba; Pictet; Forbion Ventures; Schroders; BioGeneration Ventures",
    "Description": "Dutch biotech; brain-penetrant azasugar for lysosomal storage disorders (GM1/GM2/NPC); funds two late-stage trials.",
    "Therapeutic Area": "Rare metabolic / Lysosomal storage disorders (GM1, GM2 gangliosidosis; NPC)",
    "Therapeutic Modality": "Oral small\u2011molecule azasugar (nizubaglustat)",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "Yes (azasugar)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Netherlands"
  },
  {
    "Company": "Stylus Medicine",
    "Funding date": "2025-05-13",
    "Funding round": "A",
    "Funding amount": "$85M",
    "Investors": "RA Capital; Khosla; Chugai Venture Fund; Eli Lilly; J&J Innovation; Myeloma Investment Fund; Tachyon",
    "Description": "Developing next-gen in vivo genetic medicines; series A includes extension; CEO Emile Nuwaysir ex-BlueRock.",
    "Therapeutic Area": "Genetic medicines / In vivo gene editing",
    "Therapeutic Modality": "In vivo genetic medicine using engineered recombinases + LNP delivery",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (genetic medicine)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Haya Therapeutics",
    "Funding date": "2025-05-08",
    "Funding round": "A",
    "Funding amount": "$65M",
    "Investors": "Sofinnova; Earlybird; Eli Lilly; ATHOS; +ND; Alexandria; LifeLink; Apollo; Longview; 4see; BERNINA; Schroders",
    "Description": "Precision RNA-guided regulatory genome targeting therapeutics; funds to launch clinical trials for HTX-001 in heart failure; expand engine; Lilly obesity deal up to $1B biobucks.",
    "Therapeutic Area": "Cardiometabolic / Heart failure; chronic & age\u2011related diseases",
    "Therapeutic Modality": "RNA\u2011guided therapeutic targeting regulatory genome (lncRNA)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (RNA/regulatory genome targeting)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "NewLimit",
    "Funding date": "2025-05-06",
    "Funding round": "B",
    "Funding amount": "$130M",
    "Investors": "Kleiner Perkins; Nat Friedman/Daniel Gross; Khosla; Human Capital; Valor; Dimension; Founders Fund; Brian Armstrong",
    "Description": "Anti-aging; developing liver-rejuvenating mRNA medicine using LNP-delivered mRNA coding transcription factors; preclinical; expanding team.",
    "Therapeutic Area": "Regenerative medicine / Aging (liver rejuvenation)",
    "Therapeutic Modality": "LNP\u2011delivered mRNA encoding rejuvenating transcription factors",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (mRNA)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Granite Bio",
    "Funding date": "2025-04-24",
    "Funding round": "A & B",
    "Funding amount": "$100M",
    "Investors": "Versant; Novartis Venture Fund; Forbion; Sanofi Ventures",
    "Description": "Funds to advance antibody candidates incl. GRT-001 draining pro-inflammatory monocytes; Phase 1a in healthy volunteers; Phase 1b IBD later this year.",
    "Therapeutic Area": "Immunology / Autoimmune & inflammatory diseases (incl. IBD)",
    "Therapeutic Modality": "Monoclonal antibody depleting pro\u2011inflammatory monocytes (GRT\u2011001)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No (antibodies)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Etiome",
    "Funding date": "2025-04-24",
    "Funding round": NaN,
    "Funding amount": "$50M",
    "Investors": "Flagship Pioneering",
    "Description": "Platform mapping disease progression over time to identify targets and timing; developing 'preemptive medicines' initially for metabolic, neurodegenerative, autoimmune diseases and cancers.",
    "Therapeutic Area": "Multi\u2011therapeutic (metabolic, neurodegenerative, inflammatory, oncology \u2013 preemptive medicine)",
    "Therapeutic Modality": "AI\u2011enabled preemptive medicines platform (Temporal Biodynamics; Biostaged Medicines)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear (platform)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Glycomine",
    "Funding date": "2025-04-16",
    "Funding round": "C",
    "Funding amount": "$115M",
    "Investors": "CTI Life Sciences Fund; abrdn; Advent; Novo Holdings; Sanofi Ventures; Abingworth; RiverVest; Sanderling; Chiesi Ventures; Remiges; Asahi Kasei Ventures",
    "Description": "San Carlos, CA-based; funds Phase 2b study of GLM101 mannose-1-phosphate replacement therapy for PMM2-CDG rare disease.",
    "Therapeutic Area": "Rare metabolic / Congenital disorder of glycosylation (PMM2\u2011CDG)",
    "Therapeutic Modality": "Mannose\u20111\u2011phosphate replacement therapy (small\u2011molecule sugar prodrug)",
    "Lead Clinical Stage": "Clinical Phase 2b",
    "Small molecule modality?": "No (replacement therapy)",
    "HQ City": "San Carlos",
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Attovia Therapeutics",
    "Funding date": "2025-04-15",
    "Funding round": "C",
    "Funding amount": "$90M",
    "Investors": "Deep Track; Vida; Sanofi Ventures; Mirae Asset; Frazier; venBio; Goldman Sachs Alternatives; Nextech; Cormorant; EcoR1; Marshall Wace; Illumina Ventures",
    "Description": "Anti-IL31 biologic ATTO-1310 (Phase 1) for chronic pruritus; ATTO-3712 anti-IL13 x IL3 bispecific (preclinical) for atopic dermatitis and others; funds clinical development and platform.",
    "Therapeutic Area": "Dermatology / Immunology (chronic pruritus; atopic dermatitis\u2011associated itch)",
    "Therapeutic Modality": "Biologic (half\u2011life\u2011extended anti\u2011IL\u201131 antibody \u2013 ATTOBODY)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No (biologics)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Imbria Pharmaceuticals",
    "Funding date": "2025-04-10",
    "Funding round": "B",
    "Funding amount": "$57.5M",
    "Investors": "Deep Track; AN Ventures; Catalio; Cytokinetics; RA Capital; SV Health",
    "Description": "Cardiometabolic; advancing ninerafaxstat (partial fatty acid oxidation inhibitor) Phase 2b in nHCM; topline data expected late 2026.",
    "Therapeutic Area": "Cardiovascular / Cardiometabolic (non\u2011obstructive hypertrophic cardiomyopathy)",
    "Therapeutic Modality": "Oral small\u2011molecule partial fatty acid oxidation (pFOX) inhibitor",
    "Lead Clinical Stage": "Clinical Phase 2b",
    "Small molecule modality?": "Yes (inhibitor)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Neurona Therapeutics",
    "Funding date": "2025-04-03",
    "Funding round": NaN,
    "Funding amount": "$102M",
    "Investors": "Fidelity; The Column Group; Soleus; Viking; Cormorant; Schroders; LYFE; Euclidean; UCB Ventures; Willett; UC Investments; YK Bioventures; Berkeley Frontier Fund; Ysios; Alexandria; Spur Capital",
    "Description": "Allogeneic cell therapy NRTX-1001 for epilepsy; funding to advance through Phase 3; ongoing Phase 1/2 trials in MTLE.",
    "Therapeutic Area": "CNS / Neurology (drug\u2011resistant mesial temporal lobe epilepsy)",
    "Therapeutic Modality": "Allogeneic inhibitory neuron cell therapy (GABAergic interneuron; NRTX\u20111001)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No (cell therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Atsena Therapeutics",
    "Funding date": "2025-04-02",
    "Funding round": "C",
    "Funding amount": "$150M",
    "Investors": "Bain Capital; Sofinnova Investments; Abingworth; Wellington; Lightstone; Foundation Fighting Blindness; Hatteras; Osage University Partners; Manning Family Foundation",
    "Description": "Funds gene therapy ATSN-201 for X-linked retinoschisis; Phase 1/2 Lighthouse; updated data expected later this year.",
    "Therapeutic Area": "Ophthalmology / Inherited retinal disease (X\u2011linked retinoschisis)",
    "Therapeutic Modality": "AAV gene therapy (subretinal ATSN\u2011201)",
    "Lead Clinical Stage": "Clinical Phase 1/2/3 (LIGHTHOUSE adaptive trial)",
    "Small molecule modality?": "No (gene therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Isomorphic Labs",
    "Funding date": "2025-03-31",
    "Funding round": "N/A (external round)",
    "Funding amount": "$600M",
    "Investors": "Thrive Capital (lead); GV; Alphabet (follow-on)",
    "Description": "AI drug discovery; funds next-gen AI drug design model; expand programs and team.",
    "Therapeutic Area": "Multi\u2011therapeutic (AI\u2011first small\u2011molecule drug discovery across multiple TAs)",
    "Therapeutic Modality": "AI\u2011enabled drug discovery platform (modality\u2011agnostic; primarily small molecules)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear (platform)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Epicrispr Biotechnologies",
    "Funding date": "2025-03-26",
    "Funding round": "B",
    "Funding amount": "$68M",
    "Investors": "Ally Bridge Group; SOLVE FSHD; other investors",
    "Description": "South San Francisco-based; funds clinical entry of EPI-321 for facioscapulohumeral muscular dystrophy; trial in New Zealand.",
    "Therapeutic Area": "Neuromuscular / Rare disease (facioscapulohumeral muscular dystrophy \u2013 FSHD)",
    "Therapeutic Modality": "Epigenetic gene regulation therapy delivered via viral vector (EPI\u2011321)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No (epigenetic therapy / gene regulation)",
    "HQ City": "South San Francisco",
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Character Biosciences",
    "Funding date": "2025-03-25",
    "Funding round": "B",
    "Funding amount": "$93M",
    "Investors": "aMoon; Luma Group; Bausch + Lomb; Jefferson Life Sciences; Endeavors; Catalio; S32; KdT Ventures",
    "Description": "Eye disease; funds to take AMD assets CTX203 and CTX114 into clinic; expand pipeline (AMD and glaucoma).",
    "Therapeutic Area": "Ophthalmology (dry AMD and primary open\u2011angle glaucoma)",
    "Therapeutic Modality": "Small\u2011molecule / precision therapies targeting retinal cell death (CTX203, CTX114)",
    "Lead Clinical Stage": "Preclinical (entering Phase 1/2)",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Hillstar Bio",
    "Funding date": "2025-03-25",
    "Funding round": "A",
    "Funding amount": "$67M",
    "Investors": "Droia; Frazier; Novo Holdings; LifeArc; Hummingbird Bioscience",
    "Description": "Boston-based launch; precision-driven autoimmune; lead asset targeting TRBV9 T cells to clinic next year.",
    "Therapeutic Area": "Immunology / Autoimmune diseases (axial spondyloarthritis, HLA\u2011B27\u2013associated)",
    "Therapeutic Modality": "Biologic (selective TRBV9+ T\u2011cell\u2013depleting therapy)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (cell-depleting approach; modality unclear)",
    "HQ City": "Boston",
    "HQ State/Region": "MA",
    "HQ Country": "USA"
  },
  {
    "Company": "Augustine Therapeutics",
    "Funding date": "2025-03-24",
    "Funding round": "A",
    "Funding amount": "$84.8M",
    "Investors": "Jeito; Novo Holdings; Asabys; Eli Lilly; AdBio; V-Bio; PMV; VIB; Gemma Frisius; CMT Research Foundation; Newton Biocapital",
    "Description": "French biotech; HDAC6 inhibitor AGT-100216 Phase 2 PoC in Charcot-Marie-Tooth; pipeline expansion into cardiometabolic/neurodegeneration.",
    "Therapeutic Area": "Neurology / Rare peripheral neuropathy (Charcot\u2011Marie\u2011Tooth disease)",
    "Therapeutic Modality": "Oral small\u2011molecule HDAC6 inhibitor",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes (HDAC6 inhibitor)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "France"
  },
  {
    "Company": "Tempero Bio",
    "Funding date": "2025-03-24",
    "Funding round": "B",
    "Funding amount": "$70M",
    "Investors": "8VC; Aditum Bio; Khosla; other unnamed investors",
    "Description": "Substance use disorder; funds Phase 2 trials of TMP-301 (mGluR5 negative allosteric modulator) in alcohol and cocaine use disorder; phase 3-enabling and pipeline work.",
    "Therapeutic Area": "CNS / Psychiatry (alcohol and substance use disorders)",
    "Therapeutic Modality": "Oral small\u2011molecule mGluR5 negative allosteric modulator (TMP\u2011301)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes (NAM)",
    "HQ City": NaN,
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Ampersand Biomedicines",
    "Funding date": "2025-03-19",
    "Funding round": "B",
    "Funding amount": "$65M",
    "Investors": "Flagship Pioneering; Eli Lilly; other new investors",
    "Description": "Computational platform to program biologic medicines; funds to advance immuno-inflammation and immuno-oncology programs into IND-enabling.",
    "Therapeutic Area": "Immunology & Oncology (immuno\u2011inflammation and immuno\u2011oncology)",
    "Therapeutic Modality": "Biologic AND\u2011Body\u2122 programmable antibodies (computationally designed)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (biologics)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Arbor Biotechnologies",
    "Funding date": "2025-03-18",
    "Funding round": "C",
    "Funding amount": "$73.9M",
    "Investors": "Arch Venture Partners; TCGX; QIA; Partners Investment; Revelation; Kerna; existing investors",
    "Description": "CRISPR-based gene editing therapy ABO-101 for primary hyperoxaluria type 1; also rare liver disease and ALS programs.",
    "Therapeutic Area": "Rare metabolic / Renal (primary hyperoxaluria type 1)",
    "Therapeutic Modality": "LNP\u2011delivered CRISPR gene editing therapy (ABO\u2011101)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No (gene editing)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Maxion Therapeutics",
    "Funding date": "2025-03-17",
    "Funding round": "A",
    "Funding amount": "$72M",
    "Investors": "General Catalyst (lead); British Patient Capital; Solasta; Eli Lilly; LifeArc; Monograph; BGF",
    "Description": "UK biotech; KnotBody antibody platform for ion channels/GPCRs; lead MAX001 preclinical for inflammatory diseases; other pain/CV programs.",
    "Therapeutic Area": "Ion channel\u2011 and GPCR\u2011driven diseases (multi\u2011therapeutic; e.g., CNS, pain)",
    "Therapeutic Modality": "Antibody\u2011based KnotBody\u00ae biologics",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (antibody platform)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "UK"
  },
  {
    "Company": "Latigo Biotherapeutics",
    "Funding date": "2025-03-17",
    "Funding round": "B",
    "Funding amount": "$150M",
    "Investors": "Blue Owl; Deep Track; Access Biotechnology; Qatar Investment Authority; Sanofi Ventures",
    "Description": "Non-opioid pain; advancing oral small-molecule Nav1.8 inhibitors LTG-001 and LTG-305; LTG-001 in Phase 1.",
    "Therapeutic Area": "Pain / Analgesia (acute and chronic pain)",
    "Therapeutic Modality": "Oral small\u2011molecule Nav1.8 inhibitors (LTG\u2011001, LTG\u2011305)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Curevo Vaccine",
    "Funding date": "2025-03-17",
    "Funding round": "B",
    "Funding amount": "$110M",
    "Investors": "Medicxi; OrbiMed; Sanofi Ventures; HBM Healthcare; RA Capital; Janus Henderson; Adjuvant Capital; GC Biopharma",
    "Description": "Seattle-based; funds Phase 2 extension for shingles vaccine amezosvatein (non-mRNA adjuvanted sub-unit) to rival Shingrix.",
    "Therapeutic Area": "Infectious disease (shingles / herpes zoster)",
    "Therapeutic Modality": "Adjuvanted protein subunit vaccine (amezosvatein)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No (vaccine)",
    "HQ City": "Seattle",
    "HQ State/Region": "WA",
    "HQ Country": "USA"
  },
  {
    "Company": "Lila Sciences",
    "Funding date": "2025-03-10",
    "Funding round": "Seed",
    "Funding amount": "$200M",
    "Investors": "Flagship Pioneering; General Catalyst; March Capital; ARK Venture Fund; Altitude; Blue Horizon; Michigan Retirement System; Modi Ventures; Abu Dhabi Investment Authority subsidiary",
    "Description": "Developing AI for fully autonomous research labs; claims breakthroughs in genetic medicines and antibody discovery/validation.",
    "Therapeutic Area": "Platform (AI\u2011driven autonomous labs across life & materials sciences)",
    "Therapeutic Modality": "AI / autonomous lab platform (no lead therapeutic; supports genetic medicines & antibodies)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear (platform)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Garuda Therapeutics",
    "Funding date": "2025-03-04",
    "Funding round": "A-1",
    "Funding amount": "$50M",
    "Investors": "OrbiMed; Northpond; Cormorant; Kyowa Kirin",
    "Description": "Off-the-shelf cell therapies for blood disorders; advance hematopoietic stem cell transplantation candidate into clinic for bone marrow failure and beta thalassemia; manufacturing and team.",
    "Therapeutic Area": "Hematology / Blood and bone marrow disorders (HSC transplantation)",
    "Therapeutic Modality": "Off\u2011the\u2011shelf hematopoietic stem cell (HSC) therapies",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (cell therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Callio Therapeutics",
    "Funding date": "2025-03-03",
    "Funding round": "A",
    "Funding amount": "$187M",
    "Investors": "Frazier; Jeito; Novo Holdings; Omega; ClavystBio; Platanus; Norwest; Pureos; SEEDS Capital; EDBI",
    "Description": "HER2-targeted dual-payload ADC licensed from Hummingbird; launched by Frazier; shared CEO/backers with licensor.",
    "Therapeutic Area": "Oncology (HER2\u2011positive solid tumors)",
    "Therapeutic Modality": "Antibody\u2011drug conjugate (HER2\u2011targeted dual\u2011payload ADC)",
    "Lead Clinical Stage": "Clinical Phase 1 (entering first\u2011in\u2011human)",
    "Small molecule modality?": "No (ADC)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Eikon Therapeutics",
    "Funding date": "2025-02-26",
    "Funding round": "D",
    "Funding amount": "$350.7M",
    "Investors": "Lux Capital; Alexandria Venture Investments; AME Cloud; The Column Group; E15 VC; Foresite; General Catalyst; Soros Capital; StepStone; T. Rowe Price; UC Investments; others",
    "Description": "Cancer-focused; funds clinical trials incl. Phase 3 of TLR7/8 agonist immune modulator for advanced melanoma.",
    "Therapeutic Area": "Oncology (advanced melanoma)",
    "Therapeutic Modality": "Small\u2011molecule TLR7/8 agonist immune modulator (EIK1001)",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "Unclear (immune modulator)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Bambusa Therapeutics",
    "Funding date": "2025-02-14",
    "Funding round": "A",
    "Funding amount": "$90M",
    "Investors": "RA Capital; Janus Henderson; Redmile; Invus; ADAR1 Capital; other existing investors",
    "Description": "Boston biotech; next-gen bispecific antibodies for I&I; funds Phase 1 for lead programs incl. BBT001 (bispecific antibody).",
    "Therapeutic Area": "Immunology / Dermatology (atopic dermatitis & inflammatory skin diseases)",
    "Therapeutic Modality": "Half\u2011life\u2011extended bispecific antibody (blocks IL\u20114R\u03b1 and IL\u201131; BBT001)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No (bispecific antibodies)",
    "HQ City": "Boston",
    "HQ State/Region": "MA",
    "HQ Country": "USA"
  },
  {
    "Company": "Newleos Therapeutics",
    "Funding date": "2025-02-13",
    "Funding round": "A",
    "Funding amount": "$93.5M",
    "Investors": "Goldman Sachs Alternatives; Longwood Fund; Novo Holdings; DCVC Bio; Arkin Bio Capital",
    "Description": "Boston-based; acquired clinical-stage oral small molecules from Roche; funds proof-of-concept trials across programs.",
    "Therapeutic Area": "CNS / Neuropsychiatry (anxiety, substance use disorders, cognitive impairment)",
    "Therapeutic Modality": "Oral small\u2011molecule CNS drugs (Roche\u2011in\u2011licensed pipeline)",
    "Lead Clinical Stage": "Clinical Phase 2 (multiple clinical\u2011stage assets)",
    "Small molecule modality?": "Yes",
    "HQ City": "Boston",
    "HQ State/Region": "MA",
    "HQ Country": "USA"
  },
  {
    "Company": "Abcuro",
    "Funding date": "2025-02-12",
    "Funding round": "C",
    "Funding amount": "$200M",
    "Investors": "NEA; Foresite; RA Capital; Bain Capital Life Sciences; Redmile; Samsara; Sanofi Ventures; Pontifax; Mass General Brigham Ventures; New Leaf; abrdn; BlackRock; Eurofarma Ventures; Soleus",
    "Description": "Sanofi-backed; advance anti-KLRG1 antibody ulviprubart (ABC008) through Phase 2/3 muscle disease trial with goal toward regulators.",
    "Therapeutic Area": "Neuromuscular / Muscle disease (inclusion body myositis \u2013 IBM)",
    "Therapeutic Modality": "Monoclonal antibody targeting KLRG1 (ulviprubart / ABC008)",
    "Lead Clinical Stage": "Clinical Phase 2/3",
    "Small molecule modality?": "No (antibody)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "AdvanCell",
    "Funding date": "2025-02-03",
    "Funding round": "C",
    "Funding amount": "$112M",
    "Investors": "SV Health; Sanofi Ventures; Abingworth; SymBiosis; Morningside; Tenmile; Brandon Capital; others",
    "Description": "Australian radiopharma; funds Phase 1/2 study of Pb-212 targeted alpha therapy ADVC001 in metastatic prostate cancer.",
    "Therapeutic Area": "Oncology (metastatic prostate cancer)",
    "Therapeutic Modality": "Targeted alpha radiopharmaceutical therapy (Pb\u2011212\u2013labeled ADVC001)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No (radiopharma)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Australia"
  },
  {
    "Company": "Atalanta Therapeutics",
    "Funding date": "2025-01-28",
    "Funding round": "B",
    "Funding amount": "$97M",
    "Investors": "EQT Life Sciences; Sanofi Ventures; F-Prime; Novartis Venture Fund; RiverVest; abrdn; Pictet Alternative Advisors; Mirae Asset; GHR Foundation",
    "Description": "siRNA candidates for epilepsy and Huntington\u2019s; funds to launch clinical trials; CNS gene silencing approach.",
    "Therapeutic Area": "CNS / Neurology (Huntington\u2019s disease; KCNT1\u2011related epilepsy)",
    "Therapeutic Modality": "RNA therapy (siRNA / RNAi therapeutics delivered to CNS)",
    "Lead Clinical Stage": "Preclinical (advancing to Clinical Phase 1)",
    "Small molecule modality?": "No (siRNA)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Helicore Biopharma",
    "Funding date": "2025-01-28",
    "Funding round": "A",
    "Funding amount": "$65M",
    "Investors": "Versant; OrbiMed; Longitude; Wellington",
    "Description": "California-based obesity pipeline; HCR-188 monoclonal antibody binding GIP; incretin conjugate HCR-488 to start preclinical studies.",
    "Therapeutic Area": "Metabolic / Obesity",
    "Therapeutic Modality": "Monoclonal antibody GIP ligand antagonist (HCR\u2011188)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No (mAb/conjugate)",
    "HQ City": NaN,
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Shenzhen TargetRx",
    "Funding date": "2025-01-22",
    "Funding round": "C",
    "Funding amount": "$50M",
    "Investors": "Not disclosed",
    "Description": "Joint Chinese-U.S. venture; pipeline led by Bcr-Abl allosteric inhibitor (leukemia) and ALK inhibitor (NSCLC); funds overseas clinical development.",
    "Therapeutic Area": "Oncology (chronic myeloid leukemia and other BCR\u2011ABL\u2013driven leukemias)",
    "Therapeutic Modality": "Small\u2011molecule allosteric BCR\u2011ABL inhibitor (TGRX\u2011678)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes (inhibitors)",
    "HQ City": "Shenzhen",
    "HQ State/Region": "Guangdong",
    "HQ Country": "China/USA"
  },
  {
    "Company": "Be Bio",
    "Funding date": "2025-01-15",
    "Funding round": "C",
    "Funding amount": "$92M",
    "Investors": "Nextech; ARCH; Atlas; RA Capital; Alta; Longwood; Bristol Myers Squibb; Takeda Ventures; others",
    "Description": "Continuing Phase 1/2 trial of BE-101 (B-cell medicine) in hemophilia B; funding also for BE-102 for hypophosphatasia toward clinic.",
    "Therapeutic Area": "Hematology / Rare bleeding disorder (hemophilia B)",
    "Therapeutic Modality": "Engineered B\u2011cell medicine (BE\u2011101)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No (cell therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Umoja Biopharma",
    "Funding date": "2025-01-14",
    "Funding round": "C",
    "Funding amount": "$100M",
    "Investors": "Double Point Ventures; DCVC Bio; ARK; Cormorant; MPM; Qiming USA; RTW; Alexandria; SoftBank Vision Fund 2; CaaS Capital; Emerson Collective (Yosemite); K2; Myeloma Investment Fund; Univ. of Minnesota Endowment; others",
    "Description": "Funds to bring more cell therapies into clinic; UB-VV400 in vivo lentiviral vector generating CD22 CAR-T cells in patient; studies in oncology and autoimmune.",
    "Therapeutic Area": "Oncology (hematologic cancers; solid tumors)",
    "Therapeutic Modality": "In vivo CAR\u2011T and cell therapy platform (viral + non\u2011viral gene delivery)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (cell/gene)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Normunity",
    "Funding date": "2025-01-13",
    "Funding round": "B",
    "Funding amount": "$75M",
    "Investors": "Samsara; Enavate; Regeneron Ventures; Pfizer Ventures; YK Bioventures; Canaan; Sanofi Ventures; Taiho; Osage; HongShan; Connecticut Innovations",
    "Description": "Funds Phase 1 launch (2H 2025) of T cell engager NRM-823 and other oncology pipeline targets tied to tumor-specific immune suppression.",
    "Therapeutic Area": "Immuno\u2011oncology (solid tumors)",
    "Therapeutic Modality": "Monoclonal antibodies blocking immuno\u2011suppressive pathways (e.g., endothelial immuno\u2011checkpoints)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (biologics/TCE)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Kardigan",
    "Funding date": "2025-01-10",
    "Funding round": "A",
    "Funding amount": "$300M",
    "Investors": "Perceptive Advisors; ARCH Venture Partners; Sequoia Heritage",
    "Description": "New company co-founded by ex-MyoKardia leadership; cardiology pipeline via discovery + in-licensing/acquisitions; multiple late-stage candidates.",
    "Therapeutic Area": "Oncology (solid tumors; KRAS-driven cancers)",
    "Therapeutic Modality": "Small\u2011molecule covalent inhibitors (various oncology targets)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Windward Bio",
    "Funding date": "2025-01-10",
    "Funding round": "A",
    "Funding amount": "$200M",
    "Investors": "OrbiMed; Novo Holdings; Blue Owl Healthcare Opportunities; SR One; Omega; RTW; Qiming; Quan Capital; Pivotal bioVenture",
    "Description": "Swiss biotech; improve treatment options for advanced immunological diseases; discovery pipeline of bispecifics; includes clinical-stage mAb WIN378 from Kelun-Biotech/Harbour BioMed.",
    "Therapeutic Area": "Cardiometabolic (obesity and metabolic disease)",
    "Therapeutic Modality": "Small\u2011molecule incretin\u2011enhancing therapies (oral GLP\u20111/dual mechanisms)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (mAbs/bispecifics)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Switzerland"
  },
  {
    "Company": "Ouro Medicines",
    "Funding date": "2025-01-10",
    "Funding round": "A",
    "Funding amount": "$120M",
    "Investors": "TPG Life Sciences Innovations; NEA; Norwest; Monograph; GSK; UPMC Enterprises; Boyu/Zoo; LongRiver; other unnamed investors",
    "Description": "T cell engager company for chronic immune diseases; licensed bispecific TCE OM336 from Keymed; plans to enter clinic this year for B-cell-mediated immune diseases.",
    "Therapeutic Area": "Oncology / Genetic diseases (RNA repair / editing)",
    "Therapeutic Modality": "RNA\u2011editing small\u2011molecule platform (site\u2011directed RNA repair)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (bispecific)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Numab Therapeutics",
    "Funding date": "2025-01-10",
    "Funding round": "C extension",
    "Funding amount": "$54.6M",
    "Investors": "Cormorant; Forbion Growth; HBM Healthcare; Novo Holdings; BVF; Octagon; RTW; BlackRock funds/accounts",
    "Description": "Swiss biotech; multispecific antibodies in inflammation and oncology; closing Series C total 180M CHF.",
    "Therapeutic Area": "Oncology & Immunology (multi\u2011specific biologics)",
    "Therapeutic Modality": "Multi\u2011specific antibody therapeutics (e.g., ND series programs)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No (antibodies)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Switzerland"
  },
  {
    "Company": "Timberlyne Therapeutics",
    "Funding date": "2025-01-09",
    "Funding round": "A",
    "Funding amount": "$180M",
    "Investors": "Abingworth; Bain Capital Life Sciences; Venrock; Boyu Capital; Lilly Asia Ventures; Braidwell; 3H Health Investment",
    "Description": "US-based builder Mountainfield + China's Keymed launched; focused on CD38-targeting IgG1 mAb CM313 (ex-China rights) with milestones/royalties/equity stake.",
    "Therapeutic Area": "Immunology / Respiratory (asthma, COPD)",
    "Therapeutic Modality": "Small\u2011molecule immune\u2011modulating therapies",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (mAb)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "USA/China"
  },
  {
    "Company": "Light Horse Therapeutics",
    "Funding date": "2025-01-09",
    "Funding round": "A",
    "Funding amount": "$62M",
    "Investors": "Versant; Mubadala; Bristol Myers Squibb; Taiho Ventures; AbbVie",
    "Description": "Using precision genome editing to support small-molecule drug discovery (initial cancer focus); platform finds new functional sites within targets.",
    "Therapeutic Area": "CNS (neurodegeneration; Alzheimer\u2019s, Parkinson\u2019s)",
    "Therapeutic Modality": "Mitochondrial\u2011targeted small\u2011molecule therapeutics",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes (small-molecule discovery focus)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Leyden Labs",
    "Funding date": "2025-01-09",
    "Funding round": NaN,
    "Funding amount": "$70M",
    "Investors": "ClavystBio; Polaris; Qiming; existing investors",
    "Description": "Dutch biotech; mucosal protection nasal spray platform against respiratory viruses; funds human efficacy studies for PanFlu and platform research.",
    "Therapeutic Area": "Infectious disease (broad viral respiratory protection)",
    "Therapeutic Modality": "Intranasal antibodies / intranasal biologics",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No (biologic/antiviral nasal approach unclear)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Netherlands"
  },
  {
    "Company": "Verdiva Bio",
    "Funding date": "2025-01-09",
    "Funding round": "A",
    "Funding amount": "$410M",
    "Investors": "Forbion; General Atlantic; RA Capital; OrbiMed; Logos Capital; Lilly Asia Ventures; LYFE Capital",
    "Description": "Obesity-focused; launched with three assets from Sciwind incl. weekly oral GLP-1 agonist.",
    "Therapeutic Area": "Oncology (precision radiopharmaceuticals)",
    "Therapeutic Modality": "Targeted radiotherapeutics (radiopharmaceutical platform)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes (oral GLP-1)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "UK"
  },
  {
    "Company": "A2 Biotherapeutics",
    "Funding date": "2025-01-09",
    "Funding round": "C",
    "Funding amount": "$80M",
    "Investors": "Syndicate incl. The Column Group and Samsara BioCapital",
    "Description": "Cell therapy specialist; advancing CAR-T programs based on Tmod platform; running two Phase 1/2 trials.",
    "Therapeutic Area": "Oncology (solid tumors \u2013 mesothelin\u2011expressing, HLA\u2011A*02\u2011loss)",
    "Therapeutic Modality": "Autologous logic\u2011gated CAR\u2011T cell therapy (Tmod\u2122 platform)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No (cell therapy)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Tenvie Therapeutics",
    "Funding date": "2025-01-08",
    "Funding round": NaN,
    "Funding amount": "$200M",
    "Investors": "Arch Venture Partners; F-Prime; Mubadala; other unnamed investors",
    "Description": "South San Francisco-based neurology company; houses several small-molecule assets (some from Denali); most advanced: NLRP3 inhibitor and allosteric SARM1 inhibitor in IND-enabling stage.",
    "Therapeutic Area": "CNS / Neurology (neuroinflammation, neurodegeneration, metabolic\u2011linked CNS disease)",
    "Therapeutic Modality": "Small\u2011molecule inhibitors (CNS\u2011penetrant and peripherally restricted; NLRP3 and SARM1 programs)",
    "Lead Clinical Stage": "Preclinical (IND\u2011enabling)",
    "Small molecule modality?": "Yes",
    "HQ City": "South San Francisco",
    "HQ State/Region": "CA",
    "HQ Country": "USA"
  },
  {
    "Company": "Aspect Biosystems",
    "Funding date": "2025-01-08",
    "Funding round": "B",
    "Funding amount": "$115M",
    "Investors": "Dimension (lead); Novo Nordisk; Radical Ventures; undisclosed global investment firm; InBC; Pallasite; Pangaea; Rhino; T1D Fund; others",
    "Description": "Developing bioprinted tissue therapeutics (cellular medicines) for endocrine/metabolic diseases; funds platform combining AI bioprinting, design tools, cells, biomaterials.",
    "Therapeutic Area": "Metabolic / Endocrine (diabetes and obesity)",
    "Therapeutic Modality": "Bioprinted tissue therapeutics (cell\u2011based, 3D\u2011bioprinted implants)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No (cellular/tissue)",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Alesta Therapeutics",
    "Funding date": "2025-01-08",
    "Funding round": "A",
    "Funding amount": "$67M",
    "Investors": "Frazier; Droia; Novartis Venture Fund; RTW; RV Invest; Thuja; SSI Strategy",
    "Description": "Dutch biotech; two lead oral small molecules ALE1 (hypophosphatasia) and ALE2 (Charcot-Marie-Tooth) into clinic this year.",
    "Therapeutic Area": "Rare disease / Metabolic & Neuromuscular (hypophosphatasia; Charcot\u2011Marie\u2011Tooth disease)",
    "Therapeutic Modality": "Oral small\u2011molecule therapies (ALE1, ALE2)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": "Netherlands"
  },
  {
    "Company": "AusperBio",
    "Funding date": "2024-12-26",
    "Funding round": "B",
    "Funding amount": "$73M",
    "Investors": "Led by HanKang Capital, with participation from Sherpa Capital, CDH Investments and a strategic investor, along with existing investors Qiming Venture Partners, InnoPinnacle Fund and YuanBio Venture Capital.",
    "Description": "AusperBio will use the raise to fund phase 2 development of lead asset AHB-137, an antisense oligonucleotide designed to treat chronic hepatitis B. The funds will support clinical studies in China and global trials, as well as the development of commercial-scale manufacturing processes. The biotech will also use the money to expand its therapeutic pipeline and operational capabilities. ",
    "Therapeutic Area": "Infectious disease / Hepatology (chronic hepatitis B)",
    "Therapeutic Modality": "Antisense oligonucleotide therapy (AHB\u2011137)",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Ottimo Pharma",
    "Funding date": "2024-12-19",
    "Funding round": "A",
    "Funding amount": "$140M",
    "Investors": "Led by OrbiMed, Avoro Capital and Samsara BioCapital, with blue chip investors RTW Investments, Decheng Capital, Janus Henderson Investors, J.P. Morgan Life Sciences Private Capital, Invus and founding investor Medicxi.",
    "Description": "Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured \"over\" $140 million in series A funds to push forward its potential Keytruda contender. The series A funds have been earmarked to \u201caccelerate\u201d Ottimo\u2019s lead asset, a PD1-VEGFR2 bifunctional antibody called jankistomig. The company has plans to submit an IND filing in \u201clate 2025\u201d for the candidate. ",
    "Therapeutic Area": "Oncology (solid tumors requiring PD\u20111/VEGFR2 modulation)",
    "Therapeutic Modality": "Bi\u2011functional monoclonal antibody (PD\u20111 x VEGFR2 IgG; jankistomig)",
    "Lead Clinical Stage": "Preclinical (clinic\u2011ready)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Angitia Biopharmaceuticals",
    "Funding date": "2024-12-11",
    "Funding round": "C",
    "Funding amount": "$120M",
    "Investors": "Bain Capital Life Sciences, Janus Henderson, OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital and Elikon Venture.",
    "Description": "The biotech will use the new series C funds to push its three musculoskeletal candidates through ongoing trials, the most advanced of which is AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease that is undergoing a phase 3 study. There\u2019s also AGA2118, a bispecific antibody targeting sclerostin and DKK1, which is in a phase 2 trial for osteoporosis in postmenopausal women. ",
    "Therapeutic Area": "Musculoskeletal / Bone (spinal fusion; osteoporosis; osteogenesis imperfecta)",
    "Therapeutic Modality": "Biologics (rhBMP6 fusion therapy AGA111; bone\u2011building bispecific antibodies targeting sclerostin & DKK1)",
    "Lead Clinical Stage": "Clinical Phase 3 (AGA111 registrational)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Tasca Therapeutics",
    "Funding date": "2024-12-10",
    "Funding round": "A",
    "Funding amount": "$52M",
    "Investors": "Co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group.",
    "Description": "Named after the Italian word for \u201cpocket,\u201d newly launched Tasca is using mass spectrometry-based proteomics to find proteins with unique binding sites that can be targeted by new drugs. The Boston-based biotech will use the raise to advance its lead first-in-class cancer asset, CP-383, into phase 1/2 clinical proof-of-concept studies and to expand its pipeline. ",
    "Therapeutic Area": "Oncology (advanced solid tumors incl. SCLC, CRC, HNSCC, glioblastoma)",
    "Therapeutic Modality": "Small\u2011molecule inhibitor discovered via auto\u2011palmitoylation proteomics (CP\u2011383)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": "Boston",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Citryll",
    "Funding date": "2024-12-09",
    "Funding round": "B",
    "Funding amount": "$89.8M",
    "Investors": "Johnson & Johnson Innovation (JJDC, Inc.), Forbion, Novartis Venture Fund, Pureos Bioventures, BioGeneration Ventures, Seventure Partners, BOM, Curie Capital and Citryll\u2019s founders.",
    "Description": "Dutch biotech Citryll has closed an oversubscribed series B that will help advance the clinical development of CIT-013, a monoclonal antibody targeting neutrophil extracellular traps (NETs), a component of the inflammatory process. ",
    "Therapeutic Area": "Immunology / Autoimmune & inflammatory diseases (e.g., rheumatoid arthritis)",
    "Therapeutic Modality": "Monoclonal antibody NETosis inhibitor (CIT\u2011013 targeting citrullinated histones / NETs)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Nuvig Therapeutics",
    "Funding date": "2024-12-05",
    "Funding round": "B",
    "Funding amount": "$161M",
    "Investors": "Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), Norwest Venture Partners, B Capital, Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, funds managed by abrdn, Novo Holdings, Platanus, Bristol Myers Squibb, Digitalis Ventures and Mission BioCapital.",
    "Description": "Big Pharma-backed immunomodulation biotech Nuvig Therapeutics is moving its lead asset into phase 2 trials using a $161 million war chest. ",
    "Therapeutic Area": "Immunology / Chronic autoimmune diseases (e.g., CIDP and others)",
    "Therapeutic Modality": "Biologic immunomodulator (engineered Fc\u2011based antibody\u2011like therapy; NVG\u20112089)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Antag Therapeutics",
    "Funding date": "2024-12-04",
    "Funding round": "A",
    "Funding amount": "$84M",
    "Investors": "Led by Versant Ventures, with Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures) and Export and Investment Fund of Denmark.",
    "Description": "The Danish biotech will use the funds to push its lead program, dubbed AT-7687, into the clinic for phase 1 testing. ",
    "Therapeutic Area": "Metabolic / Obesity",
    "Therapeutic Modality": "Oral small\u2011molecule GIPR antagonist (AT\u20117687)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Maze Therapeutics",
    "Funding date": "2024-12-03",
    "Funding round": "D",
    "Funding amount": "$115M",
    "Investors": "Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital, Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures and other unnamed investors.",
    "Description": "Human genetics biotech Maze Therapeutics has secured $115 million, money that will help advance lead assets MZE829 and MZE782. MZE829 is an oral APOL1 inhibitor. ",
    "Therapeutic Area": "Renal / Cardiometabolic (APOL1\u2011mediated kidney disease)",
    "Therapeutic Modality": "Oral small\u2011molecule APOL1 inhibitor (MZE829)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Adcendo",
    "Funding date": "2024-11-25",
    "Funding round": "B",
    "Funding amount": "$135M",
    "Investors": "TCGX, TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), Logos Capital, RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital.",
    "Description": "Adcendo has raised an oversubscribed $135 million series B, money that will go toward launching several antibody-drug conjugate (ADC) candidates into the clinic. ",
    "Therapeutic Area": "Oncology (underserved solid tumors)",
    "Therapeutic Modality": "Antibody\u2011drug conjugates (ADCs; e.g., TF\u2011targeting ADCs)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Enveda",
    "Funding date": "2024-11-21",
    "Funding round": "C",
    "Funding amount": "$130M",
    "Investors": "Led by Kinnevik and FPV with participation from new and existing investors Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital, True Ventures, Cresset Partners, The Nature Conservancy and Henry R. Kravis.",
    "Description": "The Boulder, Colorado-based biotech plans to use the raise to usher more drugs into the clinic in 2025 and 2026. ",
    "Therapeutic Area": "Immunology / Respiratory & Dermatology (atopic dermatitis, asthma)",
    "Therapeutic Modality": "Oral small\u2011molecule natural\u2011product\u2013derived drug (ENV\u2011294)",
    "Lead Clinical Stage": "Clinical Phase 2a",
    "Small molecule modality?": "No",
    "HQ City": "Boulder",
    "HQ State/Region": "Colorado",
    "HQ Country": "USA"
  },
  {
    "Company": "ATB Therapeutics",
    "Funding date": "2024-11-18",
    "Funding round": "A",
    "Funding amount": "$57M",
    "Investors": "Co-led by EQT Life Sciences and MRL Ventures Fund, alongside V-Bio Ventures, VIVES Partners, the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest and existing investors.",
    "Description": "Belgian biotech ATB will use the raise to expand and enhance its ATBioFarm antibody platform. ",
    "Therapeutic Area": "Oncology & Autoimmune disease",
    "Therapeutic Modality": "Plant\u2011produced weaponized antibody therapeutics (ATBody\u00ae from ATBioFarm platform)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "TRex Bio",
    "Funding date": "2024-11-13",
    "Funding round": "B",
    "Funding amount": "$84M",
    "Investors": "Led by Delos Capital, with new investors Avego BioScience Capital and Agent Capital and existing investors Eli Lilly, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Alexandria Venture Investments and Polaris Partners.",
    "Description": "The Bay Area biotech will use the raise to advance its TNFR2 agonist through early clinical studies. ",
    "Therapeutic Area": "Immunology / Autoimmune & inflammatory diseases (incl. atopic dermatitis)",
    "Therapeutic Modality": "Biologic TNFR2\u2011selective agonist antibody (TRB\u2011061)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Metsera",
    "Funding date": "2024-11-13",
    "Funding round": "B",
    "Funding amount": "$215M",
    "Investors": "Led by Wellington Management and Venrock Healthcare Capital Partners, with participation from new investors Fidelity Management & Research Company, Janus Henderson Investors, funds and accounts advised by T. Rowe Price Associates, Inc. and Rowe Price Investment Management, Inc., Viking Global Investors, Deep Track Capital and RA Capital Management, along with existing investors ARCH Venture Partners, Alpha Wave Ventures, GV, SoftBank Vision Fund 2, Newpath Partners and SymBiosis.",
    "Description": "Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 million series B. ",
    "Therapeutic Area": "Metabolic / Obesity and cardiometabolic disease",
    "Therapeutic Modality": "Incretin and non\u2011incretin therapies (oral & injectable GLP\u20111, combinations, amylin analog)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Alentis Therapeutics",
    "Funding date": "2024-11-12",
    "Funding round": "D",
    "Funding amount": "$181M",
    "Investors": "OrbiMed, Novo Holdings, Jeito Capital, Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, Avego Bioscience Capital, RA Capital Management, Morningside Venture Investments, BB Pureos and other unnamed investors.",
    "Description": "Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two antibody-drug conjugates (ADCs). ",
    "Therapeutic Area": "Oncology (CLDN1+ squamous solid tumors) & Fibrosis",
    "Therapeutic Modality": "Anti\u2011CLDN1 antibody\u2011drug conjugates and antibodies (e.g., ALE.P02)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Trace Medicine",
    "Funding date": "2024-11-12",
    "Funding round": "A",
    "Funding amount": "$101M",
    "Investors": "Third Rock Ventures, Atlas Venture, GV and RA Capital Management.",
    "Description": "Trace Medicine has launched with $101 million and a mission to treat amyotrophic lateral sclerosis (ALS). ",
    "Therapeutic Area": "Neurology (ALS driven by TDP\u201143/UNC13A)",
    "Therapeutic Modality": "Antisense oligonucleotide (ASO) therapy targeting UNC13A mRNA",
    "Lead Clinical Stage": "Preclinical (IND\u2011enabling)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Evommune",
    "Funding date": "2024-10-31",
    "Funding round": "C",
    "Funding amount": "$115M",
    "Investors": "Co-led by new investors RA Capital Management and Sectoral Asset Management, with other new investors B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures and Allostery Investments LP and existing investors Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, Symbiosis and Verition Fund Management.",
    "Description": "Evommune will use the raise to advance its lead programs in chronic urticaria and atopic dermatitis. This includes multiple phase 2 studies of small molecule EVO756. ",
    "Therapeutic Area": "Immunology / Dermatology (chronic urticaria; chronic inducible urticaria; atopic dermatitis)",
    "Therapeutic Modality": "Oral small\u2011molecule MRGPRX2 antagonist (EVO756)",
    "Lead Clinical Stage": "Clinical Phase 2b",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Axonis Therapeutics",
    "Funding date": "2024-10-30",
    "Funding round": "A",
    "Funding amount": "$115M",
    "Investors": "Co-led by Cormorant Asset Management and venBio Partners, with significant investments from Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, Lumira Ventures and Solasta Ventures.",
    "Description": "Neuromedicine firm Axonis will use the raise to advance their lead candidate, an oral small molecule for epilepsy and pain. ",
    "Therapeutic Area": "CNS / Neurology (epilepsy and neuropathic pain)",
    "Therapeutic Modality": "Oral small\u2011molecule KCC2 potentiator (AXN\u2011027)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Blue Earth Therapeutics",
    "Funding date": "2024-10-30",
    "Funding round": "A",
    "Funding amount": "$76.5M",
    "Investors": "Led by Soleus Capital and co-led by Sands Capital Management with existing investor Bracco Imaging SpA and new investors Woodline Partners and PBM Capital.",
    "Description": "British biotech Blue Earth will use the series A haul to advance its clinical-stage PSMA-targeted radioligand therapies. ",
    "Therapeutic Area": "Oncology (metastatic castration\u2011resistant prostate cancer and other PSMA+ tumors)",
    "Therapeutic Modality": "PSMA\u2011targeted radioligand / radiopharmaceutical therapies",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Pathos AI",
    "Funding date": "2024-10-29",
    "Funding round": "C",
    "Funding amount": "$62M",
    "Investors": "Led by New Enterprise Associates with participation from Revolution Growth and other existing investors, including Lightbank and Builders VC.",
    "Description": "Pathos AI has reeled in $62 million, funds that will go toward growing the biotech's team, building out its AI-based drug development platform. ",
    "Therapeutic Area": "Oncology (solid tumors; Novo-originated assets)",
    "Therapeutic Modality": "AI\u2011enabled small\u2011molecule and biologic drug development platform (modality\u2011agnostic, oncology-focused)",
    "Lead Clinical Stage": "Clinical Phase 1 (partnered asset) / Platform Preclinical",
    "Small molecule modality?": "No",
    "HQ City": "AI",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Kivu Bioscience",
    "Funding date": "2024-10-28",
    "Funding round": "A",
    "Funding amount": "$92M",
    "Investors": "Led by Novo Holdings, with participation from Gimv, Red Tree Venture Capital and HealthCap, as well as existing investors BioGeneration Ventures, M Ventures and Brabantse Ontwikkelings Maatschappij.",
    "Description": "Bay Area biotech Kivu is looking to pioneer the next generation of antibody-drug conjugates. ",
    "Therapeutic Area": "Oncology (solid tumors expressing ADC targets such as PTK7)",
    "Therapeutic Modality": "Next\u2011generation antibody\u2011drug conjugates (ADCs; e.g., KIVU\u2011107)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Agomab Therapeutics",
    "Funding date": "2024-10-25",
    "Funding round": "D",
    "Funding amount": "$89M",
    "Investors": "New investors Sanofi and Invus, as well as existing investors.",
    "Description": "The Belgian biotech will use the raise to advance its lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5, and other small molecule programs. ",
    "Therapeutic Area": "Gastroenterology (fibrostenosing Crohn\u2019s disease)",
    "Therapeutic Modality": "Oral small\u2011molecule ALK5 (TGF\u03b2R1) inhibitor, gut\u2011restricted (ontunisertib / AGMB\u2011129)",
    "Lead Clinical Stage": "Clinical Phase 2a (advancing to Phase 2b)",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Alpha-9 Oncology",
    "Funding date": "2024-10-23",
    "Funding round": "C",
    "Funding amount": "$175M",
    "Investors": "Led by Lightspeed Venture Partners and Ascenta Capital, with new investors General Catalyst, a16z Bio + Health, RA Capital Management, Janus Henderson Investors, Delos Capital, Digitalis Ventures, Lumira Ventures and a healthcare fund managed by abrdn Inc., along with existing investors Frazier Life Sciences, Longitude Capital, Nextech Invest, BVF Partners LP and Samsara BioCapital.",
    "Description": "Alpha-9 Oncology has raised a $175 million series C round to bankroll its clinical-stage radiopharmaceutical drugs. ",
    "Therapeutic Area": "Oncology (solid tumors incl. prostate, MC1R, PSMA, GRPR, CXCR4, B1R targets)",
    "Therapeutic Modality": "Targeted radiopharmaceutical therapies",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Genespire",
    "Funding date": "2024-09-25",
    "Funding round": "B",
    "Funding amount": "$52M",
    "Investors": "Co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital through its Large Venture Fund, with Indaco SGR.",
    "Description": "Italian gene therapy company Genespire has brought in \u20ac46.6 million (about $52 million) in series B funding. ",
    "Therapeutic Area": "Rare metabolic & immune diseases (inherited metabolic disorders; primary immunodeficiencies)",
    "Therapeutic Modality": "Gene therapy (immune\u2011shielded lentiviral vectors for in vivo liver delivery and ex vivo gene editing)",
    "Lead Clinical Stage": "Preclinical (first program targeting clinic ~2026)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Vicebio",
    "Funding date": "2024-09-23",
    "Funding round": "B",
    "Funding amount": "$100M",
    "Investors": "TCGX, Goldman Sachs Alternatives, Avoro Ventures, venBio, UniQuest and Medicxi.",
    "Description": "British biotech ViceBio has secured $100 million to fund an ongoing phase 1 trial of its bivalent vaccine. ",
    "Therapeutic Area": "Infectious disease (respiratory viruses \u2013 RSV & hMPV)",
    "Therapeutic Modality": "Bivalent viral vaccine (VXB\u2011241 RSV/hMPV, Molecular Clamp technology)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "GC Therapeutics",
    "Funding date": "2024-09-19",
    "Funding round": "A",
    "Funding amount": "$65M",
    "Investors": "Cormorant Asset Management, Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management and Pear VC.",
    "Description": "GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies. ",
    "Therapeutic Area": "Cell therapy / Regenerative medicine (platform across indications)",
    "Therapeutic Modality": "Programmable iPSC\u2011derived cell therapies (TFome\u2122 cell\u2011programming platform)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Superluminal Medicines",
    "Funding date": "2024-09-09",
    "Funding round": "A",
    "Funding amount": "$120M",
    "Investors": "Led by RA Capital Management with existing investors Insight Partners, NVentures (NVIDIA\u2019s venture capital arm) and Gaingels. New investors Catalio Capital Management, Eli Lilly and Company and Cooley LLP joined.",
    "Description": "Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A. ",
    "Therapeutic Area": "Metabolic / Cardiometabolic & Obesity (plus broader small\u2011molecule pipeline)",
    "Therapeutic Modality": "Structure\u2011based, AI\u2011guided small\u2011molecule therapeutics",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": "Boston",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "OrsoBio",
    "Funding date": "2024-09-06",
    "Funding round": "B",
    "Funding amount": "$67M",
    "Investors": "Co-led by new investors Ascenta Capital and Woodline Partners LP, with significant participation from existing investors Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio and Eli Lilly and Company.",
    "Description": "Obesity-focused OrsoBio will use the raise to advance its mitochondrial protonophores. The lead asset is a novel, oral, liver-targeted mitochondrial protonophore. ",
    "Therapeutic Area": "Metabolic / Obesity and associated metabolic disorders",
    "Therapeutic Modality": "Oral small\u2011molecule mitochondrial protonophore (liver\u2011targeted TLC\u20116740)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "ArsenalBio",
    "Funding date": "2024-09-04",
    "Funding round": "C",
    "Funding amount": "$325M",
    "Investors": "New investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA\u2019s venture capital arm), Luma Group, funds and accounts advised by T. Rowe Price Associates, Inc. and Rock Springs Capital, among others.",
    "Description": "Arsenal will use the oversubscribed series C to advance candidates in kidney and prostate cancer. ",
    "Therapeutic Area": "Oncology (solid tumors \u2013 ovarian, kidney, prostate cancers)",
    "Therapeutic Modality": "Autologous programmable CAR\u2011T / engineered T\u2011cell therapies",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Circle Pharma",
    "Funding date": "2024-09-03",
    "Funding round": "D",
    "Funding amount": "$90M",
    "Investors": "The Column Group, Nextech Invest and Euclidean Capital.",
    "Description": "Circle's series D will be funneled toward the clinical development of CID-078. ",
    "Therapeutic Area": "Oncology (advanced solid tumors incl. SCLC, NSCLC, other Rb\u2011dysregulated cancers)",
    "Therapeutic Modality": "Oral macrocyclic small\u2011molecule Cyclin A/B\u2011RxL inhibitor (CID\u2011078)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Navigator Medicines",
    "Funding date": "2024-08-27",
    "Funding round": "A",
    "Funding amount": "$100M",
    "Investors": "RA Capital Management and Forbion",
    "Description": "Navigator, founded earlier this year as a subsidiary of Sera Medicines, has bought itself a pipeline of OX40L-targeted mono- and bispecific antibodies. ",
    "Therapeutic Area": "Immunology / Inflammatory & autoimmune diseases (e.g., hidradenitis suppurativa)",
    "Therapeutic Modality": "Bispecific antibody targeting OX40L and TNF\u03b1 (NAV\u2011240)",
    "Lead Clinical Stage": "Clinical Phase 1b/2a",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Borealis Biosciences",
    "Funding date": "2024-08-22",
    "Funding round": "A",
    "Funding amount": "$150M",
    "Investors": "Novartis and Versant Ventures",
    "Description": "Jointly launched by Novartis and Versant, Borealis is emerging from stealth with a $150 million war chest to take on kidney disease using next-generation RNA medicines. ",
    "Therapeutic Area": "Renal / Kidney diseases",
    "Therapeutic Modality": "xRNA\u2011based RNA therapeutics (Novartis xRNA platform)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Pathalys Pharma",
    "Funding date": "2024-08-20",
    "Funding round": "B",
    "Funding amount": "$105M",
    "Investors": "TCGX, J.P. Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, Catalys Pacific and DaVita Venture Group.",
    "Description": "Pathalys has pulled in $105 million to help push its lead candidate through the final stages of clinical development. ",
    "Therapeutic Area": "Renal / Secondary hyperparathyroidism in hemodialysis patients",
    "Therapeutic Modality": "Small\u2011molecule calcimimetic (upacicalcet / PLS240)",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Red Queen Therapeutics",
    "Funding date": "2024-08-06",
    "Funding round": "A",
    "Funding amount": "$55M",
    "Investors": "Apple Tree Partners",
    "Description": "Apple Tree Partners has launched Red Queen Therapeutics, a new clinical-stage biotech developing new antiviral treatments. ",
    "Therapeutic Area": "Infectious disease (respiratory viruses \u2013 coronaviruses, influenza, RSV)",
    "Therapeutic Modality": "Stapled lipopeptide antiviral (intranasal fusion\u2011blocking peptide)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "MBX Biosciences",
    "Funding date": "2024-08-05",
    "Funding round": "C",
    "Funding amount": "$63.5M",
    "Investors": "Led by Deep Track Capital, with new investors Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates and existing investors Frazier Life Sciences, OrbiMed and Wellington Management.",
    "Description": "Hormone-oriented MBX will use the new funds to support a pipeline of peptides. ",
    "Therapeutic Area": "Endocrine & metabolic disorders",
    "Therapeutic Modality": "Precision peptide therapies (PEPs) for hormone and metabolic diseases",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Outpace Bio",
    "Funding date": "2024-08-01",
    "Funding round": "B",
    "Funding amount": "$144M",
    "Investors": "Led by RA Capital Management, with new investors Qatar Investment Authority, Surveyor Capital, Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments, and other undisclosed investors, and existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb and others.",
    "Description": "AI-powered Outpace will use the oversubscribed series B proceeds to advance multiple programmed T cell product candidates. ",
    "Therapeutic Area": "Oncology (solid tumors)",
    "Therapeutic Modality": "Engineered T\u2011cell therapies enhanced by AI\u2011designed proteins (e.g., OutSmart\u2122 IL\u20112/15)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Jade Biosciences",
    "Funding date": "2024-08-01",
    "Funding round": NaN,
    "Funding amount": "$80M",
    "Investors": "Led by Fairmount and Venrock Healthcare Capital Partners with participation by Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments and Braidwell LP.",
    "Description": "Autoimmune biotech Jade's $80 million financing will be used to support plans to develop targeted therapies. ",
    "Therapeutic Area": "Autoimmune & renal disease (IgA nephropathy; broad B\u2011cell\u2013mediated autoimmunity)",
    "Therapeutic Modality": "Monoclonal antibodies targeting APRIL and BAFF\u2011R (e.g., JADE101, JADE201)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "AIRNA",
    "Funding date": "2024-07-31",
    "Funding round": "A",
    "Funding amount": "$60M",
    "Investors": "Led by Forbion with participation from Ono Venture Investment, Alexandria Venture Investments, and other new investors, as well as AIRNA\u2019s existing syndicate, including ARCH Venture Partners and ND Capital.",
    "Description": "AIRNA\u2019s first product candidate is a treatment for alpha-1 antitrypsin deficiency. ",
    "Therapeutic Area": "Rare genetic / Metabolic (alpha\u20111 antitrypsin deficiency \u2013 AATD)",
    "Therapeutic Modality": "RNA editing therapy (AIR\u2011001; ADAR\u2011mediated RNA\u2011editing therapeutic)",
    "Lead Clinical Stage": "Clinical Phase 1/2 (entering first\u2011in\u2011human)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Confo Therapeutics",
    "Funding date": "2024-07-26",
    "Funding round": "B",
    "Funding amount": "$65.19M",
    "Investors": "Led by Ackermans & van Haaren and with new investors Driehaus Capital Management and Quest for Growth, as well as existing investors BioGeneration Ventures and others.",
    "Description": "The Belgian biotech will use the proceeds to advance two programs through phase 1 and two additional programs to IND approval, including molecules targeting GPR75. ",
    "Therapeutic Area": "Metabolic & other GPCR\u2011driven diseases (incl. obesity via GPR75)",
    "Therapeutic Modality": "Small\u2011molecule GPCR modulators",
    "Lead Clinical Stage": "Clinical Phase 1 (GPCR programs entering early trials)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Autobahn Therapeutics",
    "Funding date": "2024-07-24",
    "Funding round": "C",
    "Funding amount": "$100M",
    "Investors": "Led by Newpath Partners, with new investors Canaan Partners, Monograph Capital, and Insight Partners. Existing investors included founding investors ARCH Venture Partners and Blue Owl Healthcare Opportunities and others.",
    "Description": "The San Diego-based biotech is developing restorative treatments. Proceeds will be used to commence two Phase 2 clinical trials. ",
    "Therapeutic Area": "CNS / Neuropsychiatry & Neuroimmunology (major depressive disorder; demyelinating disorders)",
    "Therapeutic Modality": "Oral small\u2011molecule CNS\u2011targeted modulator (ABX\u2011002)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": "San Diego",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Brenig Therapeutics",
    "Funding date": "2024-07-23",
    "Funding round": "A",
    "Funding amount": "$65M",
    "Investors": "New Enterprise Associates, an additional U.S.-based healthcare investor, as well as OrbiMed, Torrey Pines Investments, BioGeneration Ventures.",
    "Description": "The Parkinson\u2019s-focused biotech will use the funds to take a LRRK2 inhibitor called BT-267 into the clinic. ",
    "Therapeutic Area": "CNS / Neurodegeneration (Parkinson\u2019s disease)",
    "Therapeutic Modality": "Oral small\u2011molecule LRRK2 inhibitor (BT\u2011267)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "GRO Biosciences",
    "Funding date": "2024-07-19",
    "Funding round": "B",
    "Funding amount": "$60M",
    "Investors": "Co-led by new investors Atlas Venture and Access Biotechnology. Returning investors Redmile Group, Digitalis Ventures, Innovation Endeavors and Leaps by Bayer.",
    "Description": "Protein therapeutics-focused biotech will use the funds to push its lead gout treatment into clinical trials. ",
    "Therapeutic Area": "Rheumatology / Metabolic (severe, refractory gout)",
    "Therapeutic Modality": "Engineered protein therapeutic incorporating non\u2011standard amino acids (ProGly\u2011Uricase)",
    "Lead Clinical Stage": "Preclinical (advancing to first\u2011in\u2011human)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "NGM Bio",
    "Funding date": "2024-07-17",
    "Funding round": "A",
    "Funding amount": "$122M",
    "Investors": "A select group of investors led by The Column Group.",
    "Description": "Cash will go towards the engineered FGF19 analog aldafermin. ",
    "Therapeutic Area": "Oncology (advanced solid tumors) & Rare metabolic / liver diseases",
    "Therapeutic Modality": "Monoclonal antibody checkpoint inhibitor (NGM707) and FGF19 analog (aldafermin)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Cardurion Pharmaceuticals",
    "Funding date": "2024-07-16",
    "Funding round": "B",
    "Funding amount": "$260M",
    "Investors": "Bain, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management and others.",
    "Description": "Support later-stage clinical trials of its two lead candidates, a PDE9 inhibitor called CRD-750 and a CaMKII inhibitor called CRD-4730. ",
    "Therapeutic Area": "Cardiovascular (chronic heart failure with reduced ejection fraction \u2013 HFrEF)",
    "Therapeutic Modality": "Oral small\u2011molecule PDE9 inhibitor (CRD\u2011750 / tovinontrine)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Scorpion Therapeutics",
    "Funding date": "2024-07-16",
    "Funding round": "C",
    "Funding amount": "$150M",
    "Investors": "Frazier Life Sciences, Lightspeed Venture Partners and others.",
    "Description": "The Boston-based biotech creates small-molecule drug candidates; funds will expand clinical development of STX-478, a PI3K\u03b1 inhibitor. ",
    "Therapeutic Area": "Oncology (PIK3CA\u2011mutant breast cancer and other advanced solid tumors)",
    "Therapeutic Modality": "Oral small\u2011molecule mutant\u2011selective PI3K\u03b1 inhibitor (STX\u2011478)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "Yes",
    "HQ City": "Boston",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "CatalYm",
    "Funding date": "2024-07-16",
    "Funding round": "D",
    "Funding amount": "$150M",
    "Investors": "NCanaan Partners, Bioqube Ventures, Forbion Growth, Omega Funds, Gilde Healthcare, Jeito Capital and others.",
    "Description": "Develop phase 2b trials for monoclonal antibody visugromab. ",
    "Therapeutic Area": "Oncology (checkpoint\u2011inhibitor\u2013refractory solid tumors; cancer cachexia)",
    "Therapeutic Modality": "Monoclonal antibody neutralizing GDF\u201115 (visugromab / CTL\u2011002)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Asceneuron",
    "Funding date": "2024-07-16",
    "Funding round": "C",
    "Funding amount": "$100M",
    "Investors": "Novo Holdings, EQT Life Sciences Dementia Fund, OrbiMed, SR One, M Ventures, Sofinnova Partners and others.",
    "Description": "Alzheimer's-focused Asceneuron plans to use funds to take the drug into phase 2. ",
    "Therapeutic Area": "CNS / Neurodegeneration (Alzheimer\u2019s, Parkinson\u2019s disease)",
    "Therapeutic Modality": "Oral small\u2011molecule O\u2011GlcNAcase (OGA) inhibitor (ASN51)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "SciRhom GmbH",
    "Funding date": "2024-07-09",
    "Funding round": "A",
    "Funding amount": "$68M",
    "Investors": "Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, Wellington Partners and others.",
    "Description": "Munich-based SciRhom designs antibodies to target inactive Rhomboid 2. ",
    "Therapeutic Area": "Immunology / Autoimmune & inflammatory diseases",
    "Therapeutic Modality": "Monoclonal antibody targeting iRhom2 (SR\u2011878) to modulate TNF\u2011\u03b1, IL\u20116R and related pathways",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": "Munich",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Myricx Bio",
    "Funding date": "2024-07-08",
    "Funding round": "A",
    "Funding amount": "$114M",
    "Investors": "Abingworth, Novo Holdings, Eli Lilly, the U.K. government\u2019s economic development bank, and founding investors Brandon Capital and Sofinnova Partners.",
    "Description": "U.K.-based Myricx will use funds to push two ADC candidates into the clinic. ",
    "Therapeutic Area": "Oncology (solid tumors)",
    "Therapeutic Modality": "Antibody\u2011drug conjugates (ADCs) with novel N\u2011myristoyltransferase inhibitor (NMTi) payloads",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Beacon Therapeutics",
    "Funding date": "2024-07-03",
    "Funding round": "B",
    "Funding amount": "$170M",
    "Investors": "Existing investors Syncona, Oxford Science Enterprises and the University of Oxford, as well as initial investments from TCGX and Advent Life Sciences.",
    "Description": "London-based Beacon develops gene therapies for retinal diseases. ",
    "Therapeutic Area": "Ophthalmology / Inherited retinal diseases (X\u2011linked retinitis pigmentosa)",
    "Therapeutic Modality": "AAV gene therapy (laru\u2011zova / laruparetigene zovaparvovec)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": "London",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Formation Bio",
    "Funding date": "2024-06-26",
    "Funding round": "D",
    "Funding amount": "$372M",
    "Investors": "a16z, Sanofi, Sequoia, Thrive, Emerson Collective, Lachy Groom, SV Angel Growth and FPV Ventures.",
    "Description": "AI-based Formation Bio plans to deploy cash to acquire and in-license clinical-stage assets. ",
    "Therapeutic Area": "Multi\u2011therapeutic (various indications; in\u2011licensed clinical\u2011stage assets)",
    "Therapeutic Modality": "Modality\u2011agnostic: AI\u2011enabled development of in\u2011licensed small molecules & biologics",
    "Lead Clinical Stage": "Clinical (Phase 1/2 across portfolio)",
    "Small molecule modality?": "No",
    "HQ City": "AI",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Exsilio Therapeutics",
    "Funding date": "2024-06-25",
    "Funding round": "A",
    "Funding amount": "$82M",
    "Investors": "Co-led by Novartis Venture Fund and Delos Capital, with OrbiMed, Insight Partners and others.",
    "Description": "Exsilio is developing genomic medicines using naturally occurring programmable genetic elements. ",
    "Therapeutic Area": "Genetic diseases (multi\u2011TA genomic medicines)",
    "Therapeutic Modality": "Redosable genomic medicines using naturally occurring programmable genetic elements via mRNA intermediates",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "iOnctura",
    "Funding date": "2024-06-20",
    "Funding round": "B",
    "Funding amount": "$86.4M",
    "Investors": "Syncona, EIC Fund, M Ventures, Inkef Capital, VI Partners, Schroders Capital, 3B Future Health Fund.",
    "Description": "Push roginolisib, an allosteric modulator of PI3K\u03b4, further into the clinic. ",
    "Therapeutic Area": "Oncology (metastatic uveal melanoma and other PI3K\u03b4\u2011driven cancers)",
    "Therapeutic Modality": "Oral small\u2011molecule allosteric PI3K\u03b4 modulator (roginolisib / IOA\u2011244)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Marea Therapeutics",
    "Funding date": "2024-06-18",
    "Funding round": "A&B",
    "Funding amount": "$190M",
    "Investors": "Third Rock Ventures, Sofinnova Investments, Forbion, Perceptive Xontogeny Venture Fund, venBio, Alpha Wave Global, Omega Funds and Surveyor Capital.",
    "Description": "Marea has emerged with $190 million and a mid-stage cardiometabolic clinical program. ",
    "Therapeutic Area": "Cardiometabolic / Cardiovascular disease (remnant cholesterol\u2013driven risk)",
    "Therapeutic Modality": "Monoclonal antibody ANGPTL4 inhibitor (MAR001)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "CinRx Pharma",
    "Funding date": "2024-05-30",
    "Funding round": NaN,
    "Funding amount": "$73M",
    "Investors": "Previous unnamed investors",
    "Description": "Hub-and-spoke biotech CinRx Pharma closed a $73 million financing. ",
    "Therapeutic Area": "Multi\u2011therapeutic (obesity, IBS, gastroparesis and other high\u2011impact indications)",
    "Therapeutic Modality": "Small\u2011molecule therapies advanced via hub\u2011and\u2011spoke clinical subsidiaries",
    "Lead Clinical Stage": "Clinical (Phase 2/3 across portfolio)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Grey Wolf Therapeutics",
    "Funding date": "2024-05-23",
    "Funding round": "B",
    "Funding amount": "$50M",
    "Investors": "Led by ICG Life Sciences, plus existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and British Patient Capital.",
    "Description": "The UK- and Australian-based drug discovery company will use the cash to support an ongoing phase 1/2 clinical trial. ",
    "Therapeutic Area": "Oncology / Immuno\u2011oncology (advanced solid tumors)",
    "Therapeutic Modality": "Oral small\u2011molecule ERAP1 inhibitor (GRWD5769) for antigen modulation",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": "Australian",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "AltruBio",
    "Funding date": "2024-05-21",
    "Funding round": "B",
    "Funding amount": "$225M",
    "Investors": "BVF Partners LP, RA Capital Management, Cormorant Asset Management, Soleus Capital, aMoon Fund and Blackstone Multi-Asset Investing, plus other unnamed investors.",
    "Description": "AltruBio raised up to $225 million. ",
    "Therapeutic Area": "Immunology / Autoimmune & inflammatory diseases (e.g., ulcerative colitis)",
    "Therapeutic Modality": "Monoclonal PSGL\u20111 agonist antibody immune checkpoint enhancer (ALTB\u2011268)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Endeavor BioMedicines",
    "Funding date": "2024-04-24",
    "Funding round": "C",
    "Funding amount": "$132.5M",
    "Investors": "AyurMaya (an affiliate of Matrix Capital Management), Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital and Woodline Partners; abrdn Inc., Ally Bridge Group and others.",
    "Description": "Endeavor will channel money into lead asset ENV-101. ",
    "Therapeutic Area": "Respiratory & Oncology",
    "Therapeutic Modality": "Small-molecule Hedgehog pathway inhibitor",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "SynOx Therapeutics",
    "Funding date": "2024-04-22",
    "Funding round": "B",
    "Funding amount": "$75M",
    "Investors": "Forbion, HealthCap and new investor Bioqube Ventures.",
    "Description": "SynOx will use funds toward a phase 3 clinical trial for emactuzumab. ",
    "Therapeutic Area": "Oncology (TGCT)",
    "Therapeutic Modality": "Monoclonal antibody (CSF1R inhibitor \u2013 emactuzumab)",
    "Lead Clinical Stage": "Clinical Phase 3",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Seaport Therapeutics",
    "Funding date": "2024-04-09",
    "Funding round": "A",
    "Funding amount": "$100M",
    "Investors": "ARCH Venture Partners, Sofinnova Investments and Third Rock Ventures.",
    "Description": "Seaport emerged with an oversubscribed $100 million series A to develop clinical-stage neuropsychiatric medicines from PureTech. ",
    "Therapeutic Area": "CNS / Neuropsychiatry",
    "Therapeutic Modality": "Oral neurosteroid prodrug",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Alterome Therapeutics",
    "Funding date": "2024-04-03",
    "Funding round": "B",
    "Funding amount": "$132M",
    "Investors": "Goldman Sachs Alternatives, Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, Orbimed, Nextech Invest, Vida Ventures, Boxer Capital and Colt Ventures.",
    "Description": "California-based Alterome has closed a $132 million series B, cash that will go toward the development of next-gen, small molecule targeted oncology therapies. ",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Small-molecule precision oncology inhibitors",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": "California",
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Neurosterix",
    "Funding date": "2024-04-03",
    "Funding round": NaN,
    "Funding amount": "$63M",
    "Investors": "Perceptive Xontogeny Venture Fund II, Perceptive Life Sciences Fund and Acorn Bioventures.",
    "Description": "Neurosterix will develop allosteric modulators to treat underserved neurological disorders. ",
    "Therapeutic Area": "CNS / Neuropsychiatric disorders",
    "Therapeutic Modality": "Allosteric modulator small molecules",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Diagonal Therapeutics",
    "Funding date": "2024-04-03",
    "Funding round": NaN,
    "Funding amount": "$128M",
    "Investors": "BVF Partners, Atlas Venture, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital and Checkpoint Capital.",
    "Description": "Diagonal raised $128 million to advance its antibody agonist-building platform. ",
    "Therapeutic Area": "Genetic & rare diseases",
    "Therapeutic Modality": "Multispecific clustering antibodies",
    "Lead Clinical Stage": "Preclinical (entering Phase 1)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Obsidian Therapeutics",
    "Funding date": "2024-04-03",
    "Funding round": "B",
    "Funding amount": "$62M",
    "Investors": "Arkin Bio Capital, Monograph Capital, Canaan Partners, F-Prime Capital and others.",
    "Description": "Obsidian cashed in on $160 million series C to advance T-cell therapy programs. March 26\u2014Avenzo Therapeutics Avenzo will funnel cash into oncology pipeline including CDK2 selective inhibitor. March 21\u2014Mirador Therapeutics Mirador aims to develop precision medicines for inflammatory and fibrotic diseases. March 20\u2014Capstan Therapeutics Capstan bagged $175 million series B to advance in vivo CAR-T pipeline. March 6\u2014Sionna Therapeutics Sionna raised a $182 million series C to advance cystic fibrosis treatments. March 4\u2014Nocion Therapeutics Nocion raised $62 million series B. ",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Engineered TIL cell therapy (mbIL15-enabled)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "BlossomHill Therapeutics",
    "Funding date": "2024-02-29",
    "Funding round": "B",
    "Funding amount": "$100M",
    "Investors": "Colt Ventures, Cormorant Asset Management, OrbiMed, Vivo Capital and others.",
    "Description": "BlossomHill raised $100 million; wants to develop small molecule drugs. ",
    "Therapeutic Area": "Oncology & Autoimmune",
    "Therapeutic Modality": "Small-molecule targeted therapies",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Kenai Therapeutics",
    "Funding date": "2024-02-29",
    "Funding round": "A",
    "Funding amount": "$82M",
    "Investors": "Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, Euclidean Capital and Saisei Ventures.",
    "Description": "Kenai uses iPSC tech for allogeneic neuron replacement cell therapies. ",
    "Therapeutic Area": "CNS / Parkinson\u2019s disease",
    "Therapeutic Modality": "Allogeneic iPSC-derived neuron replacement cell therapy",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Curve Therapeutics",
    "Funding date": "2024-02-27",
    "Funding round": "A",
    "Funding amount": "$51.8M",
    "Investors": "Pfizer Ventures, Columbus Venture Partners, British Patient Capital, Advent Life Sciences and Epidarex Capital.",
    "Description": "Curve will build out its proprietary discovery platform and advance preclinical pipeline. ",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Microcycle intracellular peptide macrocycles",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Frontier Medicines",
    "Funding date": "2024-02-22",
    "Funding round": "C",
    "Funding amount": "$80M",
    "Investors": "Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC Bio, MPM Capital and RA Capital Management.",
    "Description": "Frontier raised $80 million. ",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Covalent small-molecule inhibitors (chemoproteomics-driven)",
    "Lead Clinical Stage": "Preclinical / Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Eyconis",
    "Funding date": "2024-01-29",
    "Funding round": "A",
    "Funding amount": "$150M",
    "Investors": "Frazier Life Sciences, RA Capital Management, venBio and HealthQuest Capital",
    "Description": "Ascendis Pharma is handing over its eye disease work to new venture Eyconis. The new biotech will be based in Redwood City, California. ",
    "Therapeutic Area": "Ophthalmology",
    "Therapeutic Modality": "Long-acting ophthalmic biologics (TransCon technology)",
    "Lead Clinical Stage": "Preclinical / IND-ready",
    "Small molecule modality?": "No",
    "HQ City": "Redwood City",
    "HQ State/Region": "California",
    "HQ Country": "USA"
  },
  {
    "Company": "Synnovation Therapeutics",
    "Funding date": "2024-01-24",
    "Funding round": "A",
    "Funding amount": "$102M",
    "Investors": "Third Rock Ventures, Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management",
    "Description": "Synnovation has pulled in $102 million to develop better molecules against validated targets, namely PARP and PI3K. ",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Mutant-selective PI3K\u03b1 inhibitors",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Calluna Pharma",
    "Funding date": "2024-01-23",
    "Funding round": "A",
    "Funding amount": "$81M",
    "Investors": "Forbion, Sarsia, p53 and Investinor",
    "Description": "Oxitope Pharma and Arxx Therapeutics have merged to form Calluna. ",
    "Therapeutic Area": "Immunology & Fibrosis",
    "Therapeutic Modality": "Innate-immune modulators",
    "Lead Clinical Stage": "Preclinical / Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Lykos Therapeutics",
    "Funding date": "2024-01-05",
    "Funding round": "A",
    "Funding amount": "$100M",
    "Investors": "Helena, the Steven & Alexandra Cohen Foundation, Eir Therapeutics, Vine Ventures, True Ventures and others.",
    "Description": "MAPS PBC has rebranded to Lykos Therapeutics. ",
    "Therapeutic Area": "Neuropsychiatry (PTSD)",
    "Therapeutic Modality": "MDMA-assisted therapy",
    "Lead Clinical Stage": "Post-Phase 3 (NDA not approved)",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Claris Bio",
    "Funding date": "2024-01-04",
    "Funding round": "A",
    "Funding amount": "$57M",
    "Investors": "Novo Holdings A/S, RA Capital, Mass General Brigham Ventures and Janus Henderson Investors",
    "Description": "Claris Bio is developing CSB-001 as a topical ocular biologic. ",
    "Therapeutic Area": "Ophthalmology (corneal disease)",
    "Therapeutic Modality": "Topical biologic dHGF",
    "Lead Clinical Stage": "Preclinical / entering Phase 1",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Moonwalk Biosciences",
    "Funding date": "2024-01-04",
    "Funding round": "A",
    "Funding amount": "$57M",
    "Investors": "Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures",
    "Description": "Moonwalk emerged with $57 million to develop new epigenetic medicines. ",
    "Therapeutic Area": "Metabolic & Epigenetic diseases",
    "Therapeutic Modality": "Epigenetic editing therapeutics / siRNA",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "No",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Sudo Biosciences",
    "Funding date": "2023-12-20",
    "Funding round": "B",
    "Funding amount": "$116M",
    "Investors": "Patient Square Capital\u2019s Enavate Sciences, TPG's Life Sciences Innovations arm and The Rise Fund, Sanofi Ventures, Citadel\u2019s Surveyor Capital, Monograph Capital, Eventide Asset Management, Frazier Life Sciences and Velosity Capital.",
    "Description": "Sudo Biosciences has secured $116 million to advance programs in multiple sclerosis and psoriasis into the clinic. The fresh nine-figure haul is a far jump from Sudo\u2019s $37 million series A raised in September 2022. Since its inception in 2020, the company has collected a total of $157 million. The newest funds will go toward developing a pipeline of investigational precision tyrosine kinase 2 (TYK2) inhibitors.",
    "Therapeutic Area": "Immunology & Neuroinflammation",
    "Therapeutic Modality": "Oral allosteric TYK2 inhibitor",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Kimia Therapeutics",
    "Funding date": "2023-12-19",
    "Funding round": "A",
    "Funding amount": "$55M",
    "Investors": "The Column Group, Dimension, Horizons Ventures and individual investors",
    "Description": "After Roche paid $2.7 billion upfront to acquire Carmot Therapeutics earlier this month, the biotech's spinoff Kimia has closed a $55 million series A. Launched in January 2023, Kimia will leverage Carmot\u2019s Chemotype Evolution technology to which Kimia has a license outside the metabolic field. The new money will allow Kimia to build out its own platform and pursue a range of therapeutic targets in oncology, immunology and inflammation while continuing to partner with Carmot on certain metabolic programs.",
    "Therapeutic Area": "Multi-TA small-molecule discovery",
    "Therapeutic Modality": "AI/ML-driven small-molecule platform",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Lassen Therapeutics",
    "Funding date": "2023-12-19",
    "Funding round": "B",
    "Funding amount": "$85M",
    "Investors": "Co-led by Frazier Life Sciences and Longitude Capital, plus BVF Partners, Catalio Capital Management, Alta Partners and Longwood Capital.",
    "Description": "Lassen is back with a series B financing that will help push the fibro-inflammatory disorder biotech's medicines through the clinic. Proceeds will go towards developing LASN01 in a phase 2 study for thyroid eye disease and to get LASN500 into investigational new drug enabling studies for cancer. Lassen unveiled in 2020 with $31 million with a goal of creating antibodies for cancer and fibrosis.",
    "Therapeutic Area": "Fibrosis & Immunology",
    "Therapeutic Modality": "IL-11 receptor monoclonal antibody",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Totus Medicines",
    "Funding date": "2023-12-15",
    "Funding round": "B",
    "Funding amount": "$66M",
    "Investors": "DCVC Bio, North Pond Ventures, Camford Capital and the Regents of the University of Minnesota.",
    "Description": "Totus has closed the final tranche of a series B round totaling $66 million. The new money will go toward advancing Totus' clinical program, a mid-phase asset designed to treat PI3KCA mutant cancer, as well building out the rest of its pipeline and expanding its platform. The biotech's mission is to discover and develop small molecule medicines using DNA-encoded covalent library tech combined with artificial intelligence/machine learning.",
    "Therapeutic Area": "Oncology (pan\u2011KRAS, solid tumors)",
    "Therapeutic Modality": "Covalent small\u2011molecule KRAS inhibitors",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "EvolveImmune Therapeutics",
    "Funding date": "2023-12-13",
    "Funding round": NaN,
    "Funding amount": "$37M",
    "Investors": "Pfizer Ventures, Solasta Ventures, and Takeda Ventures, Inc., and Bristol Myers Squibb.",
    "Description": "EvolveImmune has secured $37 million with support from the venture arms of several Big Pharmas. The Connecticut-based biotech plans to use the new funds to continue building out its platform and pipeline, which includes EV-104, EvolveImmune's lead multi-functional T-cell engager program.",
    "Therapeutic Area": "Oncology (solid tumors)",
    "Therapeutic Modality": "T\u2011cell engager antibodies (TARGETED T\u2011cell activation)",
    "Lead Clinical Stage": "Preclinical / IND\u2011enabling",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Tome Biosciences",
    "Funding date": "2023-12-12",
    "Funding round": "A & B",
    "Funding amount": "$213M",
    "Investors": "Andreessen Horowitz (a16z) Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments and others.",
    "Description": "The programmable genomic integration company has launched with technology in-licensed from the Massachusetts Institute of Technology (MIT) and initial plans to develop gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.",
    "Therapeutic Area": "Genetic diseases (multi\u2011TA)",
    "Therapeutic Modality": "CRISPR\u2011based gene integration (PIPED editing)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Bicara Therapeutics",
    "Funding date": "2023-12-12",
    "Funding round": "C",
    "Funding amount": "$165M",
    "Investors": "Braidwell LP and TPG, Deerfield, Fairmount, Aisling Capital and an unnamed investor.",
    "Description": "Bicara has bagged a $165 million series C just nine months after raising a $108 million series B. The new round is quadruple the $40 million secured when the biotech launched in 2021.",
    "Therapeutic Area": "Oncology (solid tumors)",
    "Therapeutic Modality": "Bifunctional biologics (e.g., EGFR x TGF\u03b2 inhibitors)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Shinobi Therapeutics",
    "Funding date": "2023-12-12",
    "Funding round": "A",
    "Funding amount": "$51M",
    "Investors": "EQT Life Sciences, F-Prime Capital, Eight Roads Ventures Japan, Astellas Venture Management, Fast Track Initiative, JIC Venture Growth Investments and D3 LLC.",
    "Description": "Shinobi has exited stealth with an oversubscribed series A, money that will go toward advancing the company's 'Katana' iPS-T cell therapy platform and advance its first program to treat GPC3+ solid tumor cancers toward the clinic.",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Engineered stealth CAR\u2011T cell therapies",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Freya Biosciences",
    "Funding date": "2023-12-12",
    "Funding round": "A",
    "Funding amount": "$38M",
    "Investors": "Sofinnova Partners, OMX Ventures, the Export and Investment Fund of Denmark, Angelini Ventures, Mike Jafar Family Office, CE-Ventures, Corundum Systems Biology and Indaco Venture Partners.",
    "Description": "The women's health biotech has secured a $38 million series A, a financing round that will support the clinical development of Freya's lead drug candidate, a vaginal microbial immunotherapeutic designed to treat infertility. The Danish biotech will also use the new money to further build out its multi-omics data science platform.",
    "Therapeutic Area": "Women's health / Reproductive immunology",
    "Therapeutic Modality": "Live biotherapeutics (microbiome\u2011based therapeutics)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": "Danish",
    "HQ Country": NaN
  },
  {
    "Company": "ARTBIO",
    "Funding date": "2023-12-07",
    "Funding round": "A",
    "Funding amount": "$90M",
    "Investors": "Third Rock Ventures, an undisclosed healthcare fund, F-Prime Capital and Omega Funds.",
    "Description": "Even though ARTBIO launched less than six months ago with $23 million in seed funds, the radiopharmaceutical biotech is back again with a $90 million series A round. The new funds will help the biotech build out its platform.",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Alpha\u2011radioligand therapies (\u03b1\u2011RLT) using Pb\u2011212",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Odyssey Therapeutics",
    "Funding date": "2023-12-05",
    "Funding round": "C",
    "Funding amount": "$101M",
    "Investors": "Ascenta Capital, OrbiMed, SR One, General Catalyst, Foresite Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures, BlackMars Capital GmbH, Creacion Ventures, funds and accounts advised by Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, Racing Beach Ventures LLC, The Healthcare Innovation Investment Fund LLC, an investment fund associated with Leerink Partners, Ab Magnitude Ventures, KB Investment, The Global BioAccess Fund and multiple unnamed global investors.",
    "Description": "Odyssey Therapeutics has raised $101 million to help get its next-gen medicines into the clinic. The biotech currently touts 10 declared immunology and oncology programs, all of which are in preclinical or discovery stages and are either small-molecule or protein therapeutics. The newest financing round brings the Boston-based biotech\u2019s total raised to $487 million since launching in 2021.",
    "Therapeutic Area": "Oncology & Immunology",
    "Therapeutic Modality": "Small\u2011molecule precision inhibitors (covalent & allosteric)",
    "Lead Clinical Stage": "Preclinical / early clinical",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Eligo Bioscience",
    "Funding date": "2023-12-05",
    "Funding round": "B",
    "Funding amount": "$30M",
    "Investors": "Sanofi Ventures, Bpifrance, Khosla Ventures and Seventure Partners",
    "Description": "Sanofi Ventures has chipped into Eligo Bioscience\u2019s $30 million series B. Eligo is developing lead program EB005 in moderate to severe acne vulgaris.",
    "Therapeutic Area": "Infectious disease & Microbiome genetic diseases",
    "Therapeutic Modality": "CRISPR\u2011based in vivo gene editing for bacterial genomes",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Seismic Therapeutic",
    "Funding date": "2023-12-04",
    "Funding round": "B",
    "Funding amount": "$121M",
    "Investors": "Bessemer Venture Partners, Amgen Ventures, Codon Capital, Alexandria Venture Investments, Gaingels, GC&H, Timothy A. Springer, Lightspeed Venture Partners, Polaris Partners, Boxer Capital, GV, Samsara BioCapital, and unnamed management members and founders.",
    "Description": "Seismic has secured a $121 million series B that's designed to push two immunology programs into the clinic.",
    "Therapeutic Area": "Immunology / Autoimmune disease",
    "Therapeutic Modality": "AI\u2011designed biologics (machine\u2011learning optimized antibodies)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Arrivo BioVentures",
    "Funding date": "2023-11-29",
    "Funding round": "B",
    "Funding amount": "$45.25M",
    "Investors": "Orlando Health Ventures, Solas BioVentures Emerging Healthcare Fund, Rex Health Ventures and unnamed private investors",
    "Description": "The North Carolina biotech has announced the arrival of an oversubscribed series B that brings Arrivo's total capital raised to $100 million. The company will use the new money to advance SP-624, a small molecule designed to treat major depressive disorder (MDD), through a phase 2b/3 clinical trial.",
    "Therapeutic Area": "Multi\u2011TA (GI, CNS, dermatology)",
    "Therapeutic Modality": "Small\u2011molecule and biologic in\u2011licensed programs",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Aro Biotherapeutics",
    "Funding date": "2023-11-28",
    "Funding round": "B",
    "Funding amount": "$41.5M",
    "Investors": "Cowen Healthcare Investments, Johnson & Johnson Innovation, Northpond Ventures, Healthcap and BVF Partners, L.P.",
    "Description": "Philadelphia biotech Aro Biotherapeutics has raked in more than $40 million to advance its lead program, ABX1100, to treat Pompe Disease.",
    "Therapeutic Area": "Oncology & Genetic diseases",
    "Therapeutic Modality": "Centyrin\u2011siRNA conjugates (targeted RNA therapies)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Vivodyne",
    "Funding date": "2023-11-22",
    "Funding round": "Seed",
    "Funding amount": "$38M",
    "Investors": "Khosla Ventures, Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.",
    "Description": "Vivodyne has secured $38 million in seed funding to advance its drug discovery platform built to better predict drug performance in human organs.",
    "Therapeutic Area": "Platform company (multi\u2011TA)",
    "Therapeutic Modality": "AI\u2011driven large\u2011scale human tissue models for drug development",
    "Lead Clinical Stage": "Preclinical (discovery platform)",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Alto Neuroscience",
    "Funding date": "2023-11-21",
    "Funding round": "C",
    "Funding amount": "$45M",
    "Investors": "InVivium Capital, Franklin Templeton, Point72, Eli Lilly, Alexandria Venture Investments, Alpha Wave Ventures, Alpha Wave Ventures, Lightswitch Capital, partners of Alkeon Capital, WhatIf Ventures and Windham Venture Partners.",
    "Description": "The California-based biotech has closed an oversubscribed $45 million series C.",
    "Therapeutic Area": "CNS (depression, PTSD, cognitive disorders)",
    "Therapeutic Modality": "Precision psychiatry small molecules",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "NMD Pharma",
    "Funding date": "2023-11-15",
    "Funding round": "B",
    "Funding amount": "$81M",
    "Investors": "Jeito Capital, Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital and the Roche Venture Fund",
    "Description": "Backed by Novo's and Roche's venture funds, Danish biotech NMD Pharma has secured $81 million in a series B fundraise.",
    "Therapeutic Area": "Neuromuscular diseases (myasthenia gravis, ALS)",
    "Therapeutic Modality": "Small\u2011molecule ClC\u20111 inhibitors / muscle excitability modulators",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Forward Therapeutics",
    "Funding date": "2023-11-08",
    "Funding round": "A",
    "Funding amount": "$50M",
    "Investors": "BVF Partners LP, RA Capital Management and OrbiMed",
    "Description": "Curie.Bio's first partner company has set up shop. Forward Therapeutics emerged with $50 million in series A funding and a mission to advance a portfolio of small molecule immunology therapies.",
    "Therapeutic Area": "Inflammation & Fibrosis",
    "Therapeutic Modality": "Anti\u2011TL1A monoclonal antibodies",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Kynexis",
    "Funding date": "2023-11-07",
    "Funding round": "A",
    "Funding amount": "$60.9M",
    "Investors": "Forbion, Ysios Capital and Sunstone Life Science Ventures",
    "Description": "Forbion and Ysios co-founded Kynexis is launching with \u20ac57 million in series A funds to advance a small molecule KAT-II inhibitor.",
    "Therapeutic Area": "CNS / Psychiatric disorders (cocaine use disorder, schizophrenia adjunct)",
    "Therapeutic Modality": "Small\u2011molecule PDE10A inhibitor (KYN\u20115356)",
    "Lead Clinical Stage": "Clinical Phase 1/2",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Terremoto Biosciences",
    "Funding date": "2023-11-02",
    "Funding round": "B",
    "Funding amount": "$175M",
    "Investors": "New investors EcoR1 Capital, Novo Holdings and Cormorant Capital, plus existing investors OrbiMed and Third Rock Ventures.",
    "Description": "Small molecule drug discovery biotech Terremoto Biosciences has topped up its total fundraising haul to $250 million with a $175 million series B raise.",
    "Therapeutic Area": "Oncology & Immunology",
    "Therapeutic Modality": "Covalent small\u2011molecule inhibitors (chemoproteomics platform)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Gate Bioscience",
    "Funding date": "2023-11-01",
    "Funding round": "A",
    "Funding amount": "$60M",
    "Investors": "Versant Ventures, a16z Bio + Health, ARCH Venture Partners and GV",
    "Description": "Founded in 2021, Gate Bioscience has exited stealth with $60 million in hand and a plan to create a whole new class of medicines called Molecular Gates. The new potential medicine class are small molecules designed to eliminate disease-causing extracellular proteins.",
    "Therapeutic Area": "Oncology & Immunology",
    "Therapeutic Modality": "Molecular degraders targeting membrane proteins",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "MapLight Therapeutics",
    "Funding date": "2023-10-30",
    "Funding round": "C",
    "Funding amount": "$225M",
    "Investors": "Novo Holdings, 5AM Ventures, Cowen Healthcare Investments and others",
    "Description": "MapLight has picked up a large series C financing to advance its mission of developing treatments for difficult-to-treat brain disorders.",
    "Therapeutic Area": "CNS (anxiety, depression, movement disorders)",
    "Therapeutic Modality": "Small\u2011molecule neurocircuit\u2011specific modulators",
    "Lead Clinical Stage": "Preclinical / Phase 1",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Triveni Bio",
    "Funding date": "2023-10-26",
    "Funding round": "A",
    "Funding amount": "$92M",
    "Investors": "Cormorant Asset Management, Atlas Venture, OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments and other unnamed investors.",
    "Description": "Triveni Bio has unveiled with $92 million and a lead preclinical antibody program targeting eczema and asthma.",
    "Therapeutic Area": "Dermatology & Immunology",
    "Therapeutic Modality": "Monoclonal antibody against KLK7 (TRIV\u2011509)",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Rome Therapeutics",
    "Funding date": "2023-09-12",
    "Funding round": "B extension",
    "Funding amount": "$72M",
    "Investors": "Johnson & Johnson Innovation-JJDC, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, family offices Raycap and Sigmas Group, ARCH Ventures, GV, Section 32, Sanofi Ventures, Andreessen Horowitz, Mass General Brigham Ventures, Casdin Capital and Alexandria Venture Investments",
    "Description": "Rome Therapeutics has revealed a series B financing extension of $72 million that includes Big Pharma pillars Johnson & Johnson and Bristol Myers Squibb.",
    "Therapeutic Area": "Infectious Disease, Autoimmune, Oncology",
    "Therapeutic Modality": "Small\u2011molecule therapies targeting the viral \u2018dark genome\u2019",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Arialys Therapeutics",
    "Funding date": "2023-09-12",
    "Funding round": "Seed",
    "Funding amount": "$58M",
    "Investors": "Avalon BioVentures, Catalys Pacific, MPM BioImpact, Johnson & Johnson Innovation \u2013 JJDC, Inc. and Alexandria Venture Investments.",
    "Description": "A new biotech is on the block to find new treatments for neuropsychiatric diseases driven by autoimmunity.",
    "Therapeutic Area": "Neuroimmunology / Autoimmune encephalitis",
    "Therapeutic Modality": "Monoclonal antibodies targeting pathogenic autoantibodies",
    "Lead Clinical Stage": "Preclinical / IND\u2011enabling",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Mariana Oncology",
    "Funding date": "2023-09-07",
    "Funding round": "B",
    "Funding amount": "$175M",
    "Investors": "Deep Track Capital, Forbion, Atlas Venture, Access Biotechnology, RA Capital Management, Eli Lilly, Nextech Invest and Citadel\u2019s Surveyor Capital.",
    "Description": "Eli Lilly has come aboard for Mariana's oversubscribed $175 million round aimed at making waves in radiopharmaceutical development.",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Radiopharmaceuticals / Targeted radioligand therapies",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "FORE Biotherapeutics",
    "Funding date": "2023-08-23",
    "Funding round": "D",
    "Funding amount": "$75M",
    "Investors": "SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Novartis Venture Fund, 3B Future Health Fund, Cormorant Asset Management, Wellington Management and Samsung Securities.",
    "Description": "The Philadelphia-based biotech will use the $75 million for plixorafenib, the company's small molecule, orally available selective inhibitor of BRAF alterations.",
    "Therapeutic Area": "Oncology (FGFR\u2011altered tumors)",
    "Therapeutic Modality": "FGFR inhibitor small molecule (FORE8394)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Renibus Therapeutics",
    "Funding date": "2023-07-18",
    "Funding round": "B",
    "Funding amount": "$47M",
    "Investors": "New and existing investors",
    "Description": "Hot on the heels of receiving FDA breakthrough designation for its lead asset RBT-1, Renibus has closed a $47 million series B financing. The Texas-based biotech will use the new funds to advance RBT-1 through a pivotal phase 3 study.",
    "Therapeutic Area": "Cardio\u2011renal & Surgical recovery",
    "Therapeutic Modality": "Stabilized stannous prodrug (RBT\u20111)",
    "Lead Clinical Stage": "Clinical Phase 2/3",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Bitterroot Bio",
    "Funding date": "2023-06-07",
    "Funding round": "A",
    "Funding amount": "$145M",
    "Investors": "ARCH Venture Partners, Deerfield Management, GV, Koch Disruptive Technologies, Alexandria Venture Investments and other unnamed investors.",
    "Description": "Bitterroot Bio officially emerged from stealth mode following the close of its $145 million series A.",
    "Therapeutic Area": "Cardiovascular & Thrombosis",
    "Therapeutic Modality": "Anti\u2011NET biologics / immunomodulatory biologics",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "DiogenX",
    "Funding date": "2023-05-10",
    "Funding round": "A",
    "Funding amount": "$29.7M",
    "Investors": "Roche Venture Fund, Eli Lilly, Omnes, Boehringer Ingelheim Venture Fund, JDRF T1D Fund and AdBio partners.",
    "Description": "The French biotech focused on treating diabetes has raised \u20ac27.5 million ($30 million).",
    "Therapeutic Area": "Diabetes (Type 1/Type 2)",
    "Therapeutic Modality": "Pancreatic \u03b2\u2011cell regeneration small molecule (DGX\u2011001)",
    "Lead Clinical Stage": "Preclinical",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": "French",
    "HQ Country": NaN
  },
  {
    "Company": "Cullgen",
    "Funding date": "2023-05-08",
    "Funding round": "C",
    "Funding amount": "$35M",
    "Investors": "AstraZeneca-CICC Venture Capital Partnership, Sincere Capital, Voyagers Capital, Wuxi Capital Group, GNI Group Ltd.",
    "Description": "Cullgen, a biotech developing small molecule therapeutics using its targeted protein degradation tech platform, has closed a $35 million series C financing round led by Big Pharma AstraZeneca.",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Targeted protein degraders (TPD) via uSMITE platform",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "Flare Therapeutics",
    "Funding date": "2023-03-22",
    "Funding round": "B",
    "Funding amount": "$123M",
    "Investors": "GordonMD Global Investments, Pfizer Ventures, Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest, Third Rock Ventures, Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital and ShangBay Capital.",
    "Description": "The Cambridge, Massachusetts-based biotech is targeting transcription factors. The new money will be used to launch the company\u2019s first clinical trial assessing FX-909, a small-molecule inhibitor.",
    "Therapeutic Area": "Oncology",
    "Therapeutic Modality": "Small\u2011molecule transcription factor inhibitors",
    "Lead Clinical Stage": "Clinical Phase 1",
    "Small molecule modality?": "Yes",
    "HQ City": "The Cambridge",
    "HQ State/Region": "Massachusetts",
    "HQ Country": NaN
  },
  {
    "Company": "Transcend Therapeutics",
    "Funding date": "2023-02-23",
    "Funding round": "A",
    "Funding amount": "$40M",
    "Investors": "Alpha Wave Global, Integrated Investment Partners, Global Founders Capital, Emerald Development Managers and other unnamed investors",
    "Description": "The New York-based biotech has raised $40 million to help launch multiple clinical trials. Transcend is focusing on methylone.",
    "Therapeutic Area": "CNS (PTSD, depression)",
    "Therapeutic Modality": "Non-hallucinogenic MDMA\u2011analog small molecule (TSND\u2011201)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear",
    "HQ City": NaN,
    "HQ State/Region": NaN,
    "HQ Country": NaN
  },
  {
    "Company": "HighTide Therapeutics",
    "Funding date": "2023-01-05",
    "Funding round": "C/C+",
    "Funding amount": "$107M",
    "Investors": "TCM Healthcare Fund of Guangdong, Yuexiu Fund and Yuthai Fund",
    "Description": "A strong $107 million financing has swept in for Shenzhen, China-based HighTide Therapeutics.",
    "Therapeutic Area": "Gastrointestinal & Metabolic disease",
    "Therapeutic Modality": "Oral multifunctional small molecule (HTD1801)",
    "Lead Clinical Stage": "Clinical Phase 2",
    "Small molecule modality?": "Unclear",
    "HQ City": "Shenzhen",
    "HQ State/Region": NaN,
    "HQ Country": "China"
  }
]